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1 Introduction 
The term theragnostics (theranostics) was first used to describe use of information 
from imaging techniques for optimal treatment planning for an individual patient in 
oncology in 2005 (Bentzen, 2005). The term ‘theranostic’ in nuclear medicine is the 
combination of therapy and diagnostics while utilizing one drug formulation. The use of 
same drug formulation or molecular targeting vector labeled with diagnostic radionuclide 
(gamma or positron emitter) and therapeutic radionuclide (beta, alpha or auger electron 
emitter) allows molecular target specific delivery of radionuclide therapy in that patient. 
The tremendous increase in feasible production of diagnostic and therapeutic 
radionuclides for clinical use has made theranostic applications of nuclear medicine 
techniques better and presents possibility of cost effective personalized treatment 
(Bozkurt and Özcan., 2018). To achieve theranostic goal diagnostic radionuclide is 
believed to have the following properties (Dash et al., 2013; Taïeb et al., 2016) 
 It may help in evidence based optimal patient selection for radionuclide therapy 
owing to possibility of better and reliable pre-therapeutic assessment of disease 
(molecular target) burden and tumor heterogeneity by generation of low noise/ 
high resolution images. 
 It has an appropriate half-life that may not result in high radiation absorbed dose 
in patients for repeated diagnostic imaging and on the other hand is capable of 
following pharmacokinetics of complementary therapeutic radionuclide. 
 It is able to quantify and predict pre therapy radiation doses for therapeutic 
radionuclide. 
 It is able to monitor disease and objectively assesses therapeutic efficacy or 
therapy outcome. 
1.1 Overview of available theranostic radionuclides 
The role of theranostic application of radionuclides dates back to 1940’s when for 
the first time 131I was used for diagnosis as well as therapy of various thyroid disorders 
including differentiated thyroid carcinoma. It is now also considered first use of targeted 
molecular therapy directed against Na-I symporters (Verburg et al., 2014; Yordanova et 
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al., 2017a). The radionuclides that are in use with theranostic intent can be broadly 
classified into three categories. 
1.1.1 Single radionuclide with dual emissions 
Radionuclides with emission of gamma or bremsstrahlung in addition to β- particles 
have been utilized as single combination for diagnosis and therapy. Bremsstrahlung 
images with pure β- emitters like strontium-89 (89Sr) (Breen et al., 1992) or Yttrium-90 
(90Y) (Wright et al., 2015) have been employed in the past however, poor quality images 
was major drawback in its theranostic implication. 
With γ and β- emissions for diagnosis and treatment of benign and malignant 
thyroid disorders [131I]NaI is the most specific example of combined diagnosis and 
therapy in single radionuclide. Pre-therapeutic diagnosis, dosimetry and post-therapeutic 
follow up with [131I]NaI paved the way to personalized therapy in patients with thyroid 
carcinoma (Verburg et al., 2014). The dual emission iodine-131 labeled compounds in 
small (diagnostic) and large (therapeutic) doses e.g., [131I]I-MIBG for neuroendocrine 
tumors, [131I]I-tositumomab for relapsed or refractory low grade follicular or B cell non 
Hodgkin lymphoma patients and [131I]I-PSMA-1095 in metastatic castration resistant 
prostate carcinoma patients (mCRPC) are some of the other examples of theranostic 
use (Yordanova et al., 2017a). 
[188Re]Re-HEDP, [153Sm]Sm-EDTMP and [117mSn]Sn-DTPA with dual emissions 
are used for bone pain palliation in patients with metastatic bone disease (Serafini, 
2001). Likewise lutetium-177 (177Lu) with γ and β- emissions conjugated with peptides 
and macromolecule has also found wide diagnostic and therapeutic utilization in 
neuroendocrine tumors, lymphoma, metastatic bone pain palliation and mCRPC patients 
(Dash et al., 2015; Ahmadzadehfar, 2016). 
1.1.2 Sister imaging/therapeutic isotopes 
This includes combination of γ and β- emitting isotopes as well as positron (β+) and 
β- emitting isotopes of same radionuclide for theranostics. The use of gamma emitting 
isotope for planar or SPECT imaging as surrogate for therapeutic isotope can be seen 
with 123I/ 131I utilization in differentiated thyroid carcinoma (Buscombe, 2007;  Urhan et 
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al., 2007) 123I/ 131I MIBG for neuroendocrine tumors (Intenzo et al., 2007) and 123I/ 131I 
labeled MIP-1095 targeted diagnosis and therapy in mCRPC patients (Yordanova et al., 
2017a). 
Among positron/beta isotope pairs 124I/131I for differentiated thyroid carcinoma (Erdi 
et al., 1999; Nagarajah et al., 2017), 124I/131I-MIP-1095 for mCRPC (Zechmann et al., 
2014) have been utilized. Recently new theranostic pairs 86Y/90Y (Rösch et al., 2017), 
44Sc/47Sc and 64Cu/67Cu (Rösch et al, 2017) have been proposed for labeling 
biomolecules or peptides against molecular targets for diagnosis and therapy 
respectively. Theoretically β+/ β- isotope pairs are considered better than γ /β- isotope 
pairs owing to capability of better resolution and quantitation of PET for theranostic use 
but are still under investigation. 
1.1.3 Pair of different imaging and therapeutic radionuclides 
Since early 1990s, indium-111 (111In) labeled compounds as SPECT tracer are in 
use as imaging agents with complimentary β- emitting therapeutic compounds labeled 
with Yttrium-90 (90Y) and 177Lu e.g., 111In- labeled monoclonal antibodies as surrogate to 
90Y-MAb or 177Lu-MAb for pre-therapeutic patient selection as well as therapy planning 
(Bander et al., 2005). 
Owing to better imaging with PET tracers, positron emitter gallium-68 (68Ga) 
labeled vectors for diagnosis and 90Y/177Lu labeled vectors for therapy have gained wide 
acceptance as theranostic pairs. 68Ga/177Lu labeled somatostatin analogues, prostate 
specific membrane antigen, and bone seeking macromolecules as theranostic pairs in 
neuroendocrine, prostate carcinoma and metastatic bone disease patients respectively 
are in use (Yordanova et al., 2017a). Among longer lived cyclotron/ generator produced 
positron emitters 64Cu, 44Sc, 89Zr have also been proposed for labeling vectors and 
prospective dosimetry (Rösch and Baum, 2011).  
1.2 Role of dosimetry in theranostics 
According to The new European Council Directive 2013/59 article 56 (Chiesa et al., 
2017). 
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“For all medical exposure of patients for radiotherapeutic purposes, exposures of 
target volumes shall be individually planned and their delivery appropriately 
verified, taking into account that doses to non-target volumes and tissues shall be 
as low as reasonably achievable and consistent with the intended 
radiotherapeutic purpose of the exposure”. 
1.2.1 Dosimetry of diagnostic radionuclides 
As theranostics requires repeated use of diagnostic radionuclides for selection of 
right patient for right radionuclide therapy at right time and monitoring of therapy 
outcome, dosimetric analysis of these radionuclides is essential. Moreover, possible role 
in predicting pre-therapeutic dosimetric analysis for therapeutic radionuclide can provide 
information for probable incidence of clinically measureable complications of normal 
organs.  
With rapid advancements in radiopharmacy a lot of new diagnostic radio-
pharmaceuticals against molecular targets are being developed. Their translation into 
clinical practice requires comparison of biodistribution and radiation safety i.e., critical 
organ and effective dose resulting from diagnostic dose. Though animal biodistribution 
and dosimetric analysis is performed as part of pre-clinical studies and extrapolated for 
human subjects but these studies under or overestimate the radiation absorbed doses 
for humans and hence necessitate the human studies. Recent use of 124I for determining 
post therapeutic doses for 131I has opened a new venue for use of longer lived 
radionuclide labeled compounds to determine post therapeutic organ and tumor lesion 
radiation absorbed doses (Zechmann et al., 2014). 44Sc and 86Y are other nuclides that 
are proposed suitable for pre-therapeutic PET based therapeutic dose determination. 
1.2.2 Dosimetry and precision/ personalized radionuclide therapy 
The success of radionuclide therapy relies on adequate delivery of activity that is 
able to impart lethal damage to tumor tissue with tolerable level of side-effects to normal 
tissues (Ljungberg and Sjögreen Gleisner., 2016). Fixed doses versus personalized 
radionuclide therapies are under discussion since long. The role of dosimetric analysis in 
individual patient based radionuclide therapy that is prediction of administered 
radionuclide activity tailored to an individual patient which could result in adequate tumor 
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control while minimizing potential side-effects to normal tissues is imperative (Flux et al., 
2018; Strigari et al., 2014). Review of pre and intra therapeutic dosimetry for targeted 
radionuclide therapy with 131I, 177Lu and 90Y labeled compounds has clearly advocated 
the great potential of individual patient based information (Eberlein et al., 2017). It is 
further advocated that in order to explore complete potential of radionuclide therapy, 
biological effectiveness i.e., DNA damage and repair mechanisms and effect of number 
and frequency of therapy cycles on normal and tumor tissues need to be inferred along 
with  absorbed doses to normal organs and lesions obtained from dosimetric analysis 
(Eberlein et al., 2017). The progression of radiation dosimetric analysis for calculation of 
radiation absorbed doses from level of organs to tissue regions of millimeters to 
hundreds of micrometers is considered a great potential for advanced patient-specific 
dose estimates. Non-uniformities in absorbed doses with in tumor as well as surrounding 
critical structures can be displayed as dose volume histograms (DVH). In external beam 
radiotherapy (EBRT) less than 10% of non-uniformity in absorbed dose across target 
volume is considered successful. Moreover, use of tumor control probability (TCP) and 
normal tissue control probability (NTCP) in conjunction with DVH facilitates optimization 
of treatment planning. It is proposed that similar concept of treatment planning with use 
of TCP, NCTP and DVH can also be utilized for optimal treatment planning with internal  
radionuclide therapy. Thus, patient-specific dosimetry and treatment planning of 
radiolabeled substances are necessary for establishing safety of treatment and 
estimation of absorbed dose-response relationships.  
1.3 Medical Internal Radiation Dose (MIRD) system 
MIRD committee of the Society of Nuclear Medicine provides the internal dosimetry 
schema and basic methodology for calculation of absorbed doses from internally 
administered radiopharmaceutical both for diagnosis and therapeutic purposes (Bolch et 
al., 2009). MIRD schema was originally published in 1968, revised in 1976 and 
republished as MIRD primer in 1988 and 1991. MIRD schema is based on the idea that 
every radionuclide containing organ is the source of radiation exposure of other organs 
and of itself. The fraction of the radiation energy absorbed in the target organ depends 
on the physical quality of radiation (α, β, γ) and on the geometric relationships between 
source and target (distance, shape, position). MIRD schema provides framework for 
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absorbed dose assessment for whole organs, tissue sub regions, voxelized tissue 
structures as well as individual cellular compartments (Bolch et al., 2009).  
For calculation of absorbed dose to whole organs homogenous activity distribution 
is assumed in the source as well as target organs. The calculation of absorbed dose is 
governed by following equation (Bolch et al., 2009):  
     ∑  ̃                      ∑  ̃               ------------- Equation 1 
Where       is the mean energy imparted to target region (    per unit tissue 
mass delivered by cumulative activity in source region    ,   ̃      is the time-integrated 
cumulative activity or total number of nuclear transformations of radiopharmaceutical in 
source region     , and            is radionuclide specific mean absorbed dose rate 
delivered to target region      after administration per unit cumulative activity present in 
source region     .   ̃      is the fraction of administered activity in source region.      is 
the administered activity.  
S is radionuclide as well as age/ sex specific computational anatomical model 
based parameter. It is determined by equation 2 as follows (Bolch et al., 2009): 
          
∑               
   
 -------------------Equation 2 
Where      is the mean or individual energy of i
th nuclear  transition,      is the 
number of ith nuclear transition per nuclear transformation,             is the absorbed 
fraction i.e., the fraction of radiation energy    emitted within the source region    that is 
absorbed  in the target region    and       is mass of target region. 
Calculation of S value considers either pre constructed whole body computational 
phantoms representing the reference individuals of given age, sex, total body weight and 
height or a model based on segmented images of subject anatomy from CT or MRI 
images. The S values for all types of nuclei of many nuclides for combinations of source 
and target organs for a 70 kg standard human as well as models of infants, women, 
men, pregnant women and adolescents with relationships between organ and organ 
systems, including the masses have been tabulated. These extensive tables of S values 
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of various geometric models are now available from the Society of Nuclear Medicine in 
(OLINDA/EXM) commercially available software (Stabin, 2008). 
Voxel based dosimetry is possible with application of MIRD schema to voxels 
defined in PET or SPECT images. With use of voxel based S values, three dimensional 
distribution of absorbed dose is generated using calculated mean absorbed dose per 
voxel for all voxels in segmented region of the organ of interest that can be tumor or a 
region with in tumor.  As a result of non-uniformities in absorbed dose profile, mean 
absorbed dose is not adequate to interpret clinical results. Thus voxel dosimetry is used 
to generate dose-volume histograms and isodose contours. Similar to radiation 
treatment planning comparison of dose-volume histograms in tumor and surrounding 
normal tissue  can help in estimation of probability of success for internal radionuclide 
therapy and can help in tailoring the therapeutic dose to achieve desired effect at the 
target (Bolch et al., 1999, 2009). 
Dosimetric analysis thus requires (Eberlein et al., 2017; Flux et al., 2018; 
Lassmann and Eberlein, 2018): 
Quantitative measurement of pharmacokinetics: The use of MIRD schema requires 
accurate determination of activity changes within source organs with respect to time and 
in turn cumulative activity calculation. Quantitative serial imaging with gamma or positron 
emission tomography camera at optimal time points  according to MIRD pamphlet no 16 
(Siegel and Thomas, 1999), blood and urine sample collection is usually performed. 
Photon attenuation, scatter, camera limitations, voxel-based calculation of the 
distribution of energy depositions as well as image analysis, including image registration, 
image segmentation, volume of interest delineation and classification of normal tissue 
structures and tumors in the images are some of the issues that are taken into account. 
However, SPECT/CT or PET/CT has improved the quantitative accuracy owing to CT 
based volume delineation for organ and lesion dosimetry.  
Integration of time activity curve and absorbed dose calculation: After generation of time 
activity curves in source organs and tumor lesion, integration of time activity curves is 
done by optimal curve fitting. Kletting et al. has provided a proposal of obtaining optimal 
fit procedures (Eberlein et al., 2017). Cumulative activity and absorbed dose in target 
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organ can easily be determined using OLINDA/ EXM software. The software requires 
selection of suitable phantom which results in nuclide specific parameters and tabulated 
S values already entered in the buffer and is stored for further calculations. Further with 
input of pre-determined kinetic parameters as number of decays or cumulative activity in 
the organ of interest or organ system or after a possible curve fitting for integration on 
time activity data with OLINDA/ EXM software, absorbed doses to target organs can be 
calculated (Stabin, 2008). 
Patient Specific Dose Calculation: Prediction of patient specific activities tailored to 
absorbed dose limits for organs at risk e.g., kidneys in case of [177Lu]-based PRRT or 
bone marrow  in case of bone pain palliating radionuclide therapies. It is also desirable 
to predict whether tumor absorbed doses are capable of delivering significant 
therapeutic effect. Further taking into account the biological effectiveness of absorbed 
dose, dose fractionation and low dose with effective therapeutic effect is determined 
(Ljungberg and Sjögreen Gleisner, 2016) 
1.3.1 Nuclear medicine in management of bone metastasis 
Bone metastasis is a serious complication of many solid tumors. It affects more than 
75% of patients with breast and prostate cancer, and 15‑40% of patients with other 
types of tumors ( Fischer and Kampen, 2012; Macedo et al., 2017). Pain, pathological 
fractures, hypercalcemia, myelosuppression, spinal cord compression and nerve root 
lesions are the skeletal related events (SRE’s) that result in increased morbidity, 
mortality and reduced quality of life in these patients. Incidence of SREs is reported to 
be every 3-6 months that increase in frequency with disease progression (Wade et al., 
2015). The diagnosis of bone metastasis at an early stage followed by therapy improves 
survival and quality of life. 
The role of nuclear medicine is well established for diagnosis, staging and 
assessment of treatment response of skeletal metastases with use of conventional 
skeletal scintigraphy, SPECT, PET, and hybrid  SPECT/CT, PET/CT imaging (Qu et al., 
2012; Yang et al., 2011). Among these PET/CT imaging has been found the most 
sensitive and specific. Radionuclide therapy with β- and α emitting bone seeking 
radiopharmaceuticals for bone pain palliation is an important aspect in management of 
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bone pain palliation in patients with metastatic skeletal disease (Pandit-Taskar et al., 
2004). The use of imaging radionuclide and cytotoxic radionuclide therapy targeted at 
prostate specific membrane antigen (PSMA) in mCRPC patients, a new chapter in 
theranostics has emerged. It has made image guided salvage treatment of advanced 
mCRPC by targeting extracellular domain of PSMA with radiopeptides that are 
internalized upon binding and offers optimal antitumor activity, while limiting toxicity 
(Kesavan et al., 2018) . With success of PSMA based theranostics in mCRPC, efforts 
are being made to explore new theranostic radiopharmaceuticals for bone metastasis.  
1.3.2 Radiopharmaceuticals for imaging of bone metastasis 
The radiopharmaceuticals in use for diagnosis of bone metastasis can broadly be 
classified into osteotropic and oncotropics. The osteotropic radiopharmaceuticals 
includes bone seeking radiopharmaceuticals which owing to their high affinity to calcium 
hydroxyl apatite bind at sites of active bone formation or increased osteoblastic activity. 
Thus, their binding to both benign and malignant increased bone turn over sites results 
in high sensitivity and low specificity. The use of hybrid imaging like SPECT/CT or 
PET/CT is encouraged that increases the specificity. Below table 1 summarizes the 
osteotropic radiopharmaceuticals in use (Cuccurullo et al., 2013; O’Sullivan et al., 2015). 
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Tracer Radio 
pharmaceuticals 
Advantages Disadvantages 
S
P
E
C
T
 Tc-99m MDP Low cost production, easy 
availability, favorable 
dosimetry 
Non-specific as 
accumulates at both 
benign and malignant 
site.  
Tc-99m HEDP 
Tc-99m HMDP 
P
E
T
 
F-18 NaF High first pass extraction, high 
sensitivity for metastatic 
lesion  
Less specificity for 
pure lytic lesions as 
well as in  absence of 
hybrid imaging, Costly 
cyclotron production 
and less availability 
[68Ga]Ga-EDTMP, 
DOTMP, BPAMD, 
NO2AP-BP 
Easy onsite, less expensive 
generator production, have 
theranostic advantage of 
pairing with  [177Lu]Lu-
bisphosphonates or [225Ac]Ac-
bisphosphonates for therapy 
 
Table 1: Osteotropic radiopharmaceuticals (Cuccurullo et al., 2013; O’Sullivan et al., 
2015). 
In contrast oncotropic radiopharmaceuticals are the one that show uptake in 
malignant cells. The uptake is governed by specific or non-specific mechanism. The 
specific uptake is related to targeted receptor imaging found specifically in certain 
tumors. Table 2 below shows the various oncotropic radiopharmaceuticals. 
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Tracers Radiopharmaceuticals Metastasis of tumor detected (mechanism) 
S
p
e
c
if
ic
 
[131I]/ [121I]I-MIBG Pheochromocytomas, paragangliomas and 
Apudomas (Nor adrenaline analogue) 
[68Ga]Ga-DOTATOC/ 
DOTATATE, [111In]In-
octreotide  
Neuroendocrine tumors(Somatostatin analogues) 
[131I]NaI Differentiated thyroid carcinoma (Na-I symporters) 
[68Ga]Ga-PSMA Prostate carcinoma (outer domain PSMA receptor) 
N
o
n
 s
p
e
c
if
ic
 
[99mTc]Tc-MIBI/ 
tetrofosmin 
Localizes due to increased perfusion and later 
internalization with in mitochondria thus uptake 
related to increased metabolic activity of tumor cells 
[201Tl]Tl-chloride Uptake mediated through Na-K ATPase pump thus 
indicates metabolism and viability of tumor cells 
[18F]F-choline/[11C]C-
choline  
Prostate carcinoma (By up-regulated activity of 
choline kinase their uptake and later 
phosphorylation  occurs) 
[18F]FDG Uptake by a transport mechanism mediated by 
GLUT 1 (glucose transporter protein) followed by 
phosphorylation and no degradation, hence uptake 
in bone metastasis is via non-specific increased 
glucose utilization  
Table 2: Oncotropic radiopharmaceuticals(Cuccurullo et al., 2013; O’Sullivan et al., 
2015) 
1.3.3 Radionuclide therapy for bone metastasis 
Bone metastasis is a multifocal disease that results in severe bone pain at 
multiple sites. Systemic targeted radionuclide therapy provides benefit of cost effective 
bone pain palliation with minimal side effects. The palliating effect of these agents is 
mediated by their accumulation at reactive bone sites around bone metastasis resulting 
in high target-to non- target tissue ratio and a very low concentration in the surrounding 
normal bone and bone marrow. Their mode of interaction is by acting as calcium 
analogue or attaching to phosphate at osteoblastic sites. The main side effects of 
radionuclide therapy are myelosuppression and pain flare (Macedo et al., 2017). It is 
believed that radionuclide therapy causes sterilization of cells which produce 
inflammatory mediators that activate nociceptors resulting in pain palliation and 
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improved quality of life. Moreover, it is seen that repeated radionuclide therapy may 
result in tumoricidal effect as well. The therapeutic effect is dependent on type and 
energy of emissions (β- or α) from the radionuclide. The efficacy increases with con-
comitant use with hormonal therapy, chemotherapy or bisphosphonates (Fischer and 
Kampen, 2012; Pandit-Taskar et al., 2004). Table 3 gives overview of the various radio-
nuclides used for therapy. 
Radionuclides 
Half-
life 
(days) 
Maximum/ mean energy 
and maximum tissue 
range 
Gamma 
emission 
% Success 
rate 
β
- 
e
m
it
te
r 
 [32P]NaP 14.3  1.71/0.695 MeV, 8 mm No 77-84 
[186Re]Re-
HEDP 
3.7 1.07/.349 MeV, 1.1 mm Yes 50-100 
[188Re]Re-
HEDP 
0.7 2.12/- MeV, 3 mm No 60-75 
[89Sr]Sr-
Chloride 
50.5  1.46/0.58 MeV, 2.4 mm Yes 60-84 
[153Sm]Sm-
EDTMP 
1.9  0.81/0.23 MeV, 0.6 mm Yes 62-74 
[177Lu]Lu-
EDTMP 
6.7 0.497 Yes 86 
α
- 
e
m
it
te
r [
223Ra]RaCl2 11.4 28 MeV, <100 µm No Improved 
Overall 
survival 
C
o
n
v
e
rs
io
n
 
e
le
c
tr
o
n
s
 [
117mSn]Sn-
DTPA 
13.6 0.2-0.3 Yes 75 
Table 3: Therapeutic radionuclides for bone pain ( Fischer and Kampen, 2012; Pandit-
Taskar et al., 2004) 
1.4 Zoledronate based new theranostic bisphosphonates 
Since many years, bisphosphonates are in use for pain palliation and prevention of 
complications from skeletal metastases. Its anti-resorptive effect is a proven in vivo and 
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in vitro fact (Luckman et al., 1998). High rate of adsorption by bisphosphonates 
encouraged its labeling with theranostic radionuclides (Fellner et al., 2012). Alpha-
hydroxy bisphosphonates like pamidronate and, in particular, alpha-hydroxy 
bisphosphonates containing a potent nitrogen-containing moiety like zoledronate 
represent next generations of bisphosphonates (Ebetino et al., 2011; Montalvetti et al., 
2001; Russell, 2007). In addition to binding with hydroxyapatite structure of the bone, 
their interaction with the HMG CoA reductase pathway results in inhibition of farnesyl 
diphosphate synthase (FPPS) culminating in apoptosis of osteoclasts, hence exhibiting 
a biochemical target  (Fellner et al., 2012). Among them, zoledronic acid has shown 
highest FPPS inhibition and best affinity to hydroxyl apatite making it a bisphosphonate 
of choice for labeling with diagnostic and therapeutic radionuclide (Russell, 2007). The 
bifunctional chelate DOTA has facilitated labeling of these bisphosphonates with Me-
(III); 68Ga and 177Lu  for diagnosis and treatment of skeletal metastatic disease 
respectively, thus achieving a chemical goal of new theranostic development (Meckel et 
al., 2017).  
Lutetium-177 with a half-life of 6.73 days, a low range of its β- particles with 
maximum energy (Eβmax = 497 keV), gamma emissions at energies of 112 keV (6.4%) 
and 208 keV (11%), and the possibility of cost effective large scale production with high 
specific activity and radionuclide purity has  gained high acceptance as a therapeutic 
radionuclide (Dash et al., 2015). Owing to deposition of its β- energy in the lesions and 
their close environment, it is best suited for small to medium sized tumor lesions when 
labeled with a suitable carrier (Balter et al., 2015). Moreover, 177Lu labeled 
bisphosphonates  allow for a good theranostic combination with their gallium-68 labeled 
imaging counter parts using positron emission tomography (PET) (Alavi et al., 2015). 
Pre-clinical in vitro and in vivo studies with [68Ga]Ga-DOTAZOL has shown high 
hydroxyapatite binding, good target to background ratio with fast renal clearance and 
overall skeletal uptake comparable to other 68Ga labeled DOTA α-H and α-OH 
bisphosphonates as well as [18F]Na-F (Meckel et al., 2017; Pfannkuchen et al., 2017). 
Moreover, in vivo biodistribution in a single patient of prostatic carcinoma reported 
intense uptake in skeletal metastatic lesions with lower activity in background and other 
normal organs in comparison with complimentary [68Ga]Ga-PSMA image (Pfannkuchen 
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et al., 2017). Data from animal studies comparing the biodistribution and dosimetric 
analysis extrapolated for humans between [177Lu]Lu-EDTMP and [177Lu]Lu-DOTAZOL 
indicate a higher skeletal absorbed dose for [177Lu]Lu-DOTAZOL as well and present it to 
be a better agent for radionuclide therapy of bone metastases (Yousefnia et al., 2015).  
Acyclic bisphosphonates like EDTMP labeled with 68Ga and 177Lu labeled EDTMP 
i.e., [68Ga]Ga-EDTMP (Fellner et al., 2011) and [177Lu]Lu-EDTMP (Agarwal et al., 2015) 
(Yuan et al., 2013)  have been assessed as theranostic bisphosphonates. Phase I and II 
studies with [177Lu]Lu-EDTMP for pain palliation in patients with bone metastases 
secondary to breast and prostate carcinoma have delivered encouraging results 
(Agarwal et al., 2015; Alavi et al., 2015; Mazzarri et al., 2015; Shinto et al., 2014; Thapa 
et al., 2015;Yuan et al., 2013). Radiation dosimetry analysis has also shown its safety 
with low dose delivery to the kidneys in patients with breast carcinoma and mCRPC in 
comparison to other bone pain palliating agents in use (Bal et al., 2015; Balter et al., 
2015; Sharma et al., 2017). However, the lower kinetic stability of [177Lu]Lu-EDTMP 
requires a high ligand concentration which is a drawback. Also, [68Ga]Ga-EDTMP 
showed lower skeletal accumulation compared to its [177Lu]Lu-EDTMP analogue and 
could not be paired as a theranostic agent (Meckel et al., 2017).  
Bisphosphonates conjugated to macrocyclic chelators  such as BPAMD have also 
been labeled with 68Ga and 177Lu resulting in [68Ga]Ga-BPAMD (Fellner et al., 2010) 
(Passah et al., 2017) and [177Lu]Lu-BPAMD (Baum and Kulkarni, 2012; Fellner et al., 
2010; Pfannkuchen et al., 2017; Rösch and Baum, 2011). These DOTA-conjugated 
theranostic bisphosphonates have shown excellent results and represent good 
theranostic pairs (Pfannkuchen et al., 2017). 
Despite the great potential of labeled BPAMD as a theranostic pair, further 
radiopharmaceutical research demonstrated, that the NOTA-version [68Ga]Ga-NO2APBP 
(68Ga-1,4,7-triazacyclonone-1,4-diacetic acid) of that bisphosphonate not only allowed 
for more effective labeling with 68Ga, but also demonstrated superior targeting quality ( 
Holub et al., 2015; Passah et al., 2017). It is superior with high thermodynamic stability 
and kinetic inertness as compared to DOTA labeled 68Ga bisphosphonates, labeling of 
which is less efficient and more vulnerable to experimental conditions. It was 
characterized with high skeletal uptake and less kidney uptake (Holub et al., 2015). 
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However, in pre-clinical animal biodistribution studies its therapeutic counterpart 
[177Lu]Lu-NO2APBP was found inferior to [177Lu]Lu-BPAMD with less affinity to skeleton 
(Bergmann et al., 2016). Thus [68Ga]Ga-NO2APBP and [177Lu]Lu-BPAMD were proposed 
as  theranostic combination of the simple bisphosphonate. The preclinical studies with 
[68Ga]Ga-NODAGAZOL have shown comparable results to[68Ga]Ga-NO2APBP and was 
found superior to [68Ga]Ga-DOTAZOL. Recently  [68Ga]Ga-NODAGAZOL and [177Lu]Lu-
DOTAZOL have also been reported as the most effective new bisphosphonate based 
theranostic radiopharmaceuticals (Bergmann et al., 2016; Holub et al., 2015; Meckel et 
al., 2017; Nikzad et al., 2013). However, this theranostics combination requires analysis 
of [68Ga]Ga-NODAGAZOL in humans. 
Literature based comparison of [68Ga]Ga-DOTAZOL(Meckel et al., 2017) with 
[68Ga]Ga-NO2APBP (Holub et al., 2015) revealed slightly less hydroxyapatite binding 
(92.7 ±1.3 % versus 93.8 ± 4.4%) and low bone uptake at 60 min p.i. (Standard uptake 
value (SUV) of 5.27 ± 0.62 versus 6.19 ± 1.27). The in vivo biodistribution of [68Ga]Ga-
DOTAZOL in male Wistar rats showed faster kidney clearance with peak uptake in less 
than 5 min followed by clearance in comparison to [68Ga]Ga-NO2APBP that showed 
continuous uptake till 50 min followed by clearance through urinary bladder. However, 
SUV for kidneys at 60 min p.i was found to be higher for [68Ga]Ga-DOTAZOL (0.53 ± 
0.04) as compared to [68Ga]Ga-NO2APBP (0.26 ± 0.09). Evaluation of [68Ga]Ga-
NO2APBP in female breast carcinoma patients already proved its excellent ability to 
detect lesions along with favorable radiation dosimetry with very low kidney absorbed 
dose (Passah et al., 2017). However, [68Ga]Ga-DOTAZOL has not been evaluated 
clinically so far. Moreover, preclinical animal studies with alpha emitter [225Ac]Ac-
DOTAZOL has shown biokinetics similar to [68Ga]Ga-DOTAZOL and [177Lu]Lu-DOTAZOL 
and proposed its translational use with  strategies to reduce nephrotoxicity, thus 
increasing the importance of  theranostic use of [68Ga]Ga-DOTAZOL (Pfannkuchen et al., 
2018). 
Hence, [68Ga]Ga-DOTAZOL with benefit of low cost, onsite generator production of 
gallium-68 having biodistribution and skeletal uptake comparable with  [177Lu]Lu-
DOTAZOL (Meckel et al., 2017) and [225Ac]Ac-DOTAZOL(Pfannkuchen et al., 2018) 
suggests it to be better than [18F]Na-F as potential theranostic tracer allowing for patient-
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individual dosimetry. In this study we evaluated biodistribution and dosimetric analysis of 
[68Ga]Ga-DOTAZOL and [177Lu]Lu-DOTAZOL to determine their feasible use for 
theranostics in skeletal metastatic disease. 
1.5 [44Sc]Sc-PSMA-617: New theranostic radiopharmaceutical for 
metastatic castration resistant prostate carcinoma patients 
Prostate carcinoma is the second common cancer among males. The prognosis of 
prostate carcinoma is good at early stage but becomes refractory to treatment in 
advanced stages. Survival decreases to 31% with advanced metastatic disease in soft 
as well as skeletal tissue (Ahmadzadehfar et al., 2016; Rahbar et al., 2016a). High 
abundance of prostate specific membrane antigen (PSMA) is found in all prostate 
carcinoma cells that up regulates in metastatic castration resistant prostate carcinoma 
(mCRPC) (Ahmadzadehfar, 2016; Lütje et al., 2015). Since past two decades various 
studies have been conducted to evaluate several small ligands directed against external 
domain of PSMA. High affinity small ligand PSMA-617 with high tumor to background 
ratio (Benešová et al., 2015) labeled with gallium-68 (68Ga) for PET imaging and 
lutetium-177 (177Lu) for therapy of mCRPC are in use as theranostic pair for mCRPC. 
Though [68Ga]Ga-PSMA-617 has played important role in diagnosis, staging and 
treatment follow up of mCRPC with [177Lu]Lu-PSMA-617, its short half-life of 1.13 h is a 
major limitation to determine pre [177Lu]Lu-PSMA-617 therapeutic dosimetric analysis 
which has a half-life of 6.7 days. Moreover, in a recent pre-clinical comparison of 
[68Ga]Ga-PSMA-617 with [177Lu]Lu-PSMA-617, it has surfaced that in vivo binding and 
distribution also differs between the two (Umbricht et al., 2017). 
With emerging concept of theranostic radionuclides in personalized medicine, 
cyclotron/generator produced long-lived PET radionuclides are proposed as better 
diagnostic radionuclide for theranostic use specially for pre therapeutic dosimetry (Baum 
and Kulkarni, 2012). Evidence of prolonged imaging till 23.5 h and better sensitivity to 
detect lesions by [44Sc]Sc-DOTATOC with half-life of 3.9 h encouraged labeling of 
PSMA-617 with scandium-44 (Pruszyński et al., 2012; Singh et al., 2017). Recent 
comparison of in vivo kinetics and in vitro characteristics of cyclotron produced [44Sc]Sc-
PSMA-617 with [68Ga]Ga-PSMA-617, [177Lu]Lu-PSMA-617 and [68Ga]Ga-PSMA-11 
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revealed similar kinetics of [44Sc]Sc-PSMA-617 to [177Lu]Lu-PSMA-617 in contrast to 
gallium-68 labeled agents (Umbricht et al., 2017). Long half-life (3.9 h) of scandium-44 
gives added advantages of its possible transport to distant places from site of production 
(Pruszyński et al., 2012), feasible delayed imaging with [44Sc]Sc-PSMA-617and sentinel 
node imaging prior to surgery for primary prostate carcinoma. But the most pertinent is 
that it presents as better candidate for pre [177Lu]Lu-PSMA-617 therapy dosimetric 
assessment in mCRPC patients (Umbricht et al., 2017). However presence of high 
energy gamma rays (>909 KeV) is considered a drawback (Eppard et al., 2017). Hence, 
a detailed dosimetric analysis is required for establishing its safe use for purpose of 
diagnosis and prospective dosimetric analysis. 
Therapeutic success in terms of objective response with  decline in PSA levels to 
[177Lu]Lu-PSMA-617 therapy in 70% of mCRPC patients has been described 
(Ahmadzadehfar et al., 2015; Gaertner et al., 2017). In another review >50% reduction 
of serum PSA level in 30%-70% of mCRPC patients along with 10%-32% non- 
responders to [177Lu]Lu-PSMA-617 therapy have been reported (Emmett et al., 2017). 
To date no substantial reasoning for lack of response in this fraction of mCRPC patients 
is provided. However, it is proposed that high dose delivery to tumor lesions while 
maintaining safety and avoiding toxicity could be a potential solution in enhancing 
response in resistant population, thus emphasizing role of personalized dosimetry in 
these patients (Emmett et al., 2017). At present, for treatment with [177Lu]Lu-PSMA-617 
initial administered doses are based on previous experience with PRRT, and escalated 
according to ongoing individual experience of respective clinicians at various centers. 
Expression of PSMA in small intestine, proximal renal tubules and salivary glands 
in addition to prostate carcinoma cells was found responsible for toxicity and side effects 
(Ahmadzadehfar et al., 2016; Fendler et al., 2017; Yordanova et al., 2017b). Several 
[177Lu]Lu-PSMA-617 PRRT studies have revealed its safety and effectiveness. Incidence 
of grade 3 or 4 renal, hematological and salivary gland toxicity has been found to be low. 
Occasional cases of reversible or transient xerostomia or grade 2 hematological toxicity 
have been reported (Baum et al., 2016; Yordanova et al., 2017b). 
Dosimetric analysis with low pre therapeutic and high post therapeutic dose of 
[177Lu]Lu-PSMA-617 using planar / planar + SPECT imaging also reported kidneys, 
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salivary and lacrimal  glands to be the organs at risk respectively (Delker et al., 2016; 
Fendler et al., 2017; Kabasakal et al., 2015; Kratochwil et al., 2016; Kulkarni et al., 2016; 
Okamoto et al., 2017). Use of [68Ga]Ga-PSMA-617 as a surrogate radiation dosimetric 
evaluation agent also revealed similar kinetics but lower doses as compared to 
[177Lu]Lu-PSMA-617 (Afshar-Oromieh et al., 2015) .  
Use of both planar and planar + SPECT low dose [177Lu]Lu-PSMA-617 and 
[68Ga]Ga-PSMA-617 PET imaging have drawbacks and inherent limitations for 
predicting pre-therapeutic or intra-therapeutic radiation dosimetry. Pre-therapeutic 
dosimetric analysis using low dose [177Lu]Lu-PSMA-617 planar/ planar +SPECT imaging 
requires in many countries hospital stay due to radiation protection issues, multiple time 
point imaging, blood sampling and urine sample collection, which is cumbersome to 
patients as well as the hospital staff exposing them with high radiation doses. Secondly 
it gives high organ absorbed doses and has inability to determine lacrimal gland doses. 
Last but not the least low dose radiation may not interpret the biokinetics of high doses 
of [177Lu]Lu-PSMA-617 administered for therapy in patients owing to the presence of 
more unlabeled compound in therapeutic dose ( Delker et al., 2016; Kabasakal et al., 
2015; Pfestroff et al., 2015;). As mentioned earlier, [68Ga]Ga-PSMA-617 is incapable to 
follow kinetics of PSMA beyond  4 h and also computes lower absorbed doses. Hence, 
longer lived PET nuclide 44Sc labeled PSMA is seen as an alternative for pretherapeutic 
dosimetry and better dose planning in mCRPC patients. This study evaluated 
biodistribution, dosimetric analysis of [44Sc]Sc-PSMA-617 in mCRPC patients as 
surrogate marker for pre [177Lu]Lu-PSMA-617 therapy dosimetric analysis.  
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2 Materials and Methods 
This PhD research work presents evaluation of theranostic potential of zoledronate 
based bisphosphonate [68Ga]Ga-DOTAZOL and [177Lu]Lu-DOTAZOL in metastatic disease 
patients. In addition [44Sc]Sc-PSMA-617 in metastatic castration resistant prostate 
carcinoma (mCRPC) patients was evaluated. For this biodistribution and dosimetric 
analysis of [68Ga]Ga-DOTAZOL, [177Lu]Lu-DOTAZOL and [44Sc]Sc-PSMA-617  was 
assessed. Moreover, prospective post therapeutic normal organ absorbed doses for 
[177Lu]Lu-DOTAZOL and [177Lu]Lu-PSMA-617 were determined  by using pharmacokinetic 
data of [68Ga]Ga-DOTAZOL and [44Sc]Sc-PSMA-617 respectively. 
The research work was conducted at Department of Nuclear Medicine, University 
Medical Center, Bonn from April 2016 to March 2019. The studies detailed under were 
carried out in accordance to ethical standards of institutional review board and therefore 
been performed in accordance with the ethical standards laid down in the 1964  
Declaration of Helsinki from the World Medical Association and all subsequent revisions 
(1983) and its appropriate legal requirements. All patients gave their informed consent to 
all involved imaging and therapeutic procedures. 
2.1 Patient Selection 
A total of 14 patients (Pts) were enrolled, 05 Pts for [68Ga]Ga-DOTAZOL, 04 Pts for 
[177Lu]Lu-DOTAZOL and 05 patients for [44Sc]Sc-PSMA-617 biodistribution and dosimetric 
analysis. 
  For [68Ga]Ga-DOTAZOL, five patients (M: F; 4: 1) with skeletal metastatic disease 
secondary to breast carcinoma in female patients and bronchial and metastatic 
castration resistant prostate carcinoma (mCRPC) in male patients were injected 
intravenously (i.v.) with mean ± SD dose of 172.6 ± 20.07 MBq (4.66 mCi) of [68Ga]Ga-
DOTAZOL.  Table 4 summarizes the patient characteristics below 
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  PT1 PT2 PT3 PT4 PT5 mean SD 
Age 83 83 66 64 64 72 10.07 
Weight 76 76 85 82 82 80 4.02 
Sex M M F M M   
Hematoc
rit 0.4 0.41 0.34 0.39 0.37 0.38 0.03 
Dose 152 150 181 190 190 172.6 20.07 
Tumor mCRPC mCRPC Breast 
Bronchial 
carcinoma 
Bronchial 
carcinoma 
  
Previous 
therapie
s 
received 
AH*/  
CT#/ 
[¹⁷⁷Lu]Lu
-PSMA-
617 
AH*/  CT#/ 
[¹⁷⁷Lu]Lu-
PSMA-
617 
CT# + 
local 
Iradiation 
CT#/ 
denusomab, 
 nivolumab 
CT#/ 
denusomab, 
 nivolumab 
  
Table 4: Patient characteristics in which biodistribution and dosimetric analysis with 
[68Ga]Ga-DOTAZOL was studied 
The biodistribution and dosimetric analysis of [177Lu]Lu-DOTAZOL was studied in 
four male patients with metastatic skeletal disease secondary to metastatic castration 
resistant prostate carcinoma (mCRPC) or bronchial carcinoma. After confirming 
sufficient uptake in the bone metastases with [68Ga]Ga-DOTAZOL - PET/CT, these 
patients were hospitalized for treatment with [177Lu]Lu-DOTAZOL in the context of an 
individual treatment attempt as no other treatment options were left for these patients. 
All patients had normal kidney function confirmed by renal function tests as well as renal 
scintigraphy. Table 5 shows patient details along with the injected activities of [177Lu]Lu-
DOTAZOL and previous therapies received. 
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  PT1 PT2 PT3 PT4 mean  SD 
Age 83 66 64 64 69.25 9.21 
Weight 76 76 82 82 79 3.46 
Hematocrit 0.4 0.4 0.4 0.37 0.39 0.01 
Injected 
activity 6000 6000 5873 6000 5968.25 63.5 
Tumor mCRPC mCRPC 
Bronchial 
carcinoma 
Bronchial 
carcinoma 
  
Previous 
therapies 
received 
AH*/  CT#/ 
[¹⁷⁷77Lu]Lu-
PSMA-617 
AH*/CT#+ 
local 
Iradiation 
CT#/ 
denusomab, 
 nivolumab 
CT# / 
denusomab, 
 nivolumab     
Table 5: Subject details of patients receiving radionuclide therapy with [177Lu]Lu-
DOTAZOL*Antihormonal, #Chemotherapy 
 
Five men with progressive mCRPC enrolled for [177Lu]Lu-PSMA-617 therapy and 
mean age of 69±2.2 years were enrolled for [44Sc]Sc-PSMA-617 imaging. The details of 
injected activity as well as patient characteristics are given in table 6. 
  PT1 PT2 PT3 PT4 PT5 mean SD 
Age 70 72 67 70 67 69 2.2 
Weight 78 80 70 80 104 82.4 12.76 
Hematocrit 0.33 0.30 0.39 0.30 0.29 0.32 0.04 
Dose 50.00 62.23 39.61 50.00 48.95 50.16 8.04 
Injected 
Activity 
(MBq) 0.64 0.78 0.57 0.63 0.47 0.62 0.11 
 
PSA (ng/ml) 453.00 26.00 7.20 139.00 3000.00   
[177Lu]Lu-
PSMA 
cycles 3 1 2 ---- 1 
          
Other  
therapies 
received 
RT$/ 
CT#/ 
AH* AH* 
RT$/ AH*and 
bisphosphonat
e therapy RT$ 
RT$/CT#/
AH*  
 
Table 6: Subject details, injected radioactivity of [44Sc]Sc-PSMA-617 and therapies 
received (~Hematocrit, *Antihormonal, #Chemotherapy, $Radiotherapy) 
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2.2 Preparation of radiopharmaceuticals 
2.2.1 [68Ga]Ga-DOTAZOL 
Gallium-68 was obtained from a 1.85 GBq (50mCi) ⁶⁸Ge/⁶⁸Ga-generator (iThemba 
Labs; South-Africa). Radiolabeling of DOTAZOL obtained from ITG (Isotope Technologies 
Garching GmbH, Garching, Germany) was performed on a cassette module (Gaia, 
Elysia-Raytest GmbH, Germany). Development of silica TLC-plates was conducted in 
acetylacetone/acetone (1:1) for iTLC-plates. A radiochemical yield of ≥ 98% and 
radiochemical purity of ≥ 97% was obtained. 
2.2.2 [177Lu]Lu-DOTAZOL 
DOTAZOL was radiolabeled in 0.8 ml ascorbic buffer (210 mg Na-L-ascorbat + 42 
mg gentisic acid in 1 ml 0.05 N HCl) with non-carrier-added lutetium-177, both obtained 
from ITG Isotope Technologies Garching GmbH. The manual synthesis was carried out 
on a thermoshaker at a temperature of 95°C for 30 min. An aliquot of the product was 
taken and the quality control was carried out with silica-gel coated aluminium TLC-plates 
(silica 60 F 254.5x4.5 cm, Merck, Darmstadt, Germany). Analysis was performed with a 
single trace radioTLC-scanner (PET-miniGITA, Elysia-Raytest, Straubenhardt, 
Germany) and evaluation software (GinaStar TLC, Elysia-Raytest, Straubenhardt, 
Germany). Development of TLC-plate was conducted in 0.1 M citrate buffer (pH 4), 
where [177Lu]Lu-DOTAZOL was found at Rf: 0-0.1, disaggregated DOTA at Rf: 0.5, and 
unlabeled lutetium-177 at Rf:1. The second TLC-plate was developed in a mixture of 
acetylacetone, acetone and HCl (1:1:0.1), where [177Lu]Lu-DOTAZOL was found at Rf: 0-
0.1 and unlabeled lutetium-177 at Rf:1. A radiochemical yield of ≥95% and a 
radiochemical purity ≥98% was obtained. 
2.2.3 [44Sc]Sc-PSMA-617 
3 ml of scandium-44 obtained after post processing according to literature of eluted 
44Sc from prototype 185 MBq (5 mCi) 44Ti/44Sc generator (Mainz) was used to label 
GMP-grade PSMA-617 obtained from ABX (Radeberg, Germany). Quality control for 
radiochemical yield & purity was checked using TLC with 0.1M sodium citrate; ITLC 
with1:1 v/v 1 M ammonium acetate/methanol and HPLC with Nucleodur 100-3 C18 ec 
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125/4; Macherey-Nagel GmbH & Co. KG, Germany.  A radiochemical yield of 98% and 
radiochemical purity of 99% was obtained (Eppard et al., 2017) 
2.3 Data collection 
To study biodistribution of radiopharmaceuticals, blood and urine samples were 
obtained along with image acquisitions after intravenous injection of 
radiopharmaceuticals. The protocol followed for image acquisition is summarized as 
follows  
 PET/CT acquisition studies for PET radiopharmaceuticals 
 Planar whole body gamma camera scintigraphy for gamma emitting radio-
pharmaceutical 
2.3.1 PET/CT Acquisition protocol for [68Ga]Ga-DOTAZOL and [44Sc]Sc-
PSMA-617 
Siemens Biograph 2 PET/CT scanner with a 58.5 cm axial field of view and a 
16.2 cm longitudinal field of view was used for acquiring PET/CT images. The scanner 
has a spatial resolution of about 6 mm in axial and transversal direction (at a radius of 
10 mm). All patients underwent a low dose CT scan (120kV, 40mAs) of abdomen for 
attenuation correction and patient positioning with kidneys in field of view. Initial dynamic 
imaging of abdomen for 30 minutes in list mode was performed starting simultaneously 
with i.v injection of [68Ga]Ga-DOTAZOL or  [44Sc]Sc-PSMA-617. Later static skull to mid-
thigh PET/CT images were acquired at 45 min and 2.5 h post injection (p.i.) for 
[68Ga]Ga-DOTAZOL  and at 45 min, 2 and 19.5 h p.i.. for [44Sc]Sc-PSMA-617, each 
preceded by low dose CT examination for patient positioning and attenuation correction. 
Images were reconstructed using an iterative reconstruction algorithm (OSEM with 8 
iterations, 16 subsets), application of Gaussian filter of 4mm and were corrected for 
scatter. The dynamic images were reconstructed into 6 images of 300s.  
2.3.2 Planar whole body scintigraphy protocol with [177Lu]Lu-DOTAZOL 
Serial whole body planar scintigraphy (anterior and posterior views) was 
performed with dual head Symbia SPECT/CT system (Symbia T, Siemens Healthineers, 
Erlangen, Germany) at 20 min, 3, 24 and 167 h post injection (p.i). Acquisition was done 
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in supine position at a speed of 10 cm/min using LEHR collimators with 20% energy 
window centered at a photopeak of 208 keV. Images were processed using an iterative 
ordered subset maximization algorithm provided by the manufacturer into a matrix of 
256*1024. The first data set obtained at 20 min (prior to voiding of the bladder) was 
considered as reference with 100% of administered activity. A standard source of known 
activity was placed between the legs in all images at the time of acquisition. For 
conversion of counts/min to activity, the gamma camera was pre-calibrated using a 
known activity of [177Lu]Lu-DOTAZOL and imaging it at the same speed and distance of 
10 cm/min. 
2.3.3 Blood and Urine sampling 
Blood and urine samples were drawn at varying time points (table 7). Urine 
samples were collected in pre weighed containers. A 1480 WIZARDTM 3n Gamma 
counter was used to measure activity of 1ml blood and urine of [68Ga]Ga-DOTAZOL and 
[44Sc]Sc-PSMA-617 and 0.2ml blood of [177Lu]Lu-DOTAZOL samples along with known 
standards of respective radiopharmaceutical. The calibration factor determined from the 
standard activity measurement was used to determine the activity (MBq) of respective 
radiopharmaceutical in blood and urine samples. 
Sample 
type  
[68Ga]Ga-DOTAZOL [44Sc]Sc-PSMA-617 [177Lu]Lu-DOTAZOL 
Blood  5, 10, 15, 20, 25, 30, 
45 min and 2.5 h p.i. 
5, 10, 15, 20, 25, 30, 
45 min, 2 and 19.5 h 
p.i. 
20 min, 3, 8, 24 and 
167 h p.i 
 
Urine  45 min and 2.5 h p.i. 45 min and  2 h p.i. -------------------------- 
Table 7 : Time points of blood and urine sample collection 
2.4 Data analysis 
The PET/CT dynamic and static acquisition data and whole body planar (anterior 
and posterior) scintigraphy images were analyzed qualitatively to assess the 
physiological and pathological uptake of [68Ga]Ga-DOTAZOL, [44Sc]Sc-PSMA-617 and 
[177Lu]Lu-DOTAZOL respectively. The organs with increased tracer uptake were identified 
as source organs for further dosimetric analysis which were  
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 Kidneys, liver, spleen, urinary bladder, lumbar (L1-L3) vertebrae, salivary glands 
and whole body for [68Ga]Ga-DOTAZOL as shown in illustration 1e. 
 Kidneys, liver, spleen, urinary bladder, salivary glands and whole body for 
[44Sc]Sc-PSMA-617  as shown in illustration 2. 
 Kidneys, urinary bladder and skeleton for [177Lu]Lu-DOTAZOL as shown in 
illustration 1a-d. 
 
ill. 1: Planar scintigraphy (anterior and posterior views) after therapeutic application of 
[177Lu]Lu-DOTAZOLat (a) 20 min, (b) 3 h, (c) 24 h, (d) 168 h and (e) PET/CT after 
application of [68Ga]Ga-DOTAZOL in a patient with bone metastases secondary to 
bronchial carcinoma. 
 
ill. 2: Distribution of [44Sc]Sc-PSMA-617 at (A) 45min, (B) 2 h and (C) 19.5 h 
  32  
 
Pharmacokinetics of respective radiopharmaceutical were assessed qualitatively 
and quantitatively by plotting % injected dose in source organs with respect to time. 
[68Ga]Ga-DOTAZOL PET/CT images were compared visually to [68Ga]Ga-PSMA-617, 
[18F]-FDG PET/CT and [99mTc]Tc-MDP planar whole body images.  Skeletal uptake 
kinetics were assessed by comparison of lesion to normal bone SUV ratio for 
representative metastatic lesions on [68Ga]Ga-DOTAZOL with [68Ga]Ga-PSMA-617 and 
[18F]-FDG PET/CT. 
2.4.1 Dosimetric analysis with [68Ga]Ga-DOTAZOL and [44Sc]Sc-PSMA-617 
The dosimetric analysis was carried out in following steps 
 Total source organ activity was calculated in MBq by multiplying the CT based 
source organ volume (ml) with mean counts/ml (KBq/ml) determined by drawing 
volume of interest (VOI) encompassing entire source organ on CT image using 
MEDISO interview fusion software (MEDISO Medical Imaging Systems, Buda-
pest, Hungary) and dividing it with 1000. For [68Ga]Ga-DOTAZOL, skeletal activity 
was calculated by multiplying the mean counts/ml in lumbar vertebrae with 5000 
(total weight of skeleton in an adult) (ICRP, 1995). 
 Percent of injected activity in all source organs was determined. For % of injected 
activity in whole body, as legs and some part of upper arms was not imaged, 
hence instead of using total injected dose in its calculation we used estimated 
injected dose in image only. We assumed initial homogenous tracer distribution 
and scaled the injected activity proportional to % weight of body in image by using 
equation 3. Percent body weight in image was calculated by using equation 4. 
%                       
                                                 
                                  
-------Equation 3 
                   
                                                
             
  --Equation 4 
 OLINDA/EXM version 2.0 (Hermes Medical Solutions, Stockholm, Sweden) was 
used for generation of time activity curves and determination of residence time 
(MBq-h/MBq). For this fitting of mono exponential curve on whole body and 
salivary glands kinetics and bi exponential curves for kinetics of rest of source 
organs was done. Residence time for remainder of the body for [68Ga]Ga-
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DOTAZOL was calculated by fitting A × [1- exp-ʎt] function to cumulative urinary 
excretion and using method explained by M. G. Stabin (Stabin, 2008). The same 
for [44Sc]Sc-PSMA-617 was calculated by subtracting residence time of all source 
organs except  urinary bladder from whole body residence time. 
 Indirect blood based method with patient hematocrit based red marrow to blood 
ratio (RMBLR) for calculating bone marrow self-dose (Hindorf et al., 2005; 
Sgouros et al., 2000; Shen et al., 1999; Siegel, 2005) 
 To calculate residence time for urinary bladder contents, trapezoidal method was 
used taking into account urinary bladder activity in images along with activity in 
urinary samples. 
 Organ absorbed doses and effective doses/ MBq were calculated with 
OLINDA/EXM version 2.0 (Hermes Medical Solutions, Stockholm, Sweden) after 
adjusting weight of organs for patient by multiplying the reference adult male/ 
female whole body weight with factor obtained by dividing patient weight with 
reference adult (male/female) weight respectively. The mean of residence times, 
organ absorbed doses (mSv/MBq) and effective doses (mSv/MBq) were 
calculated. The total effective dose in mSv received with usual injected dose of 
150 MBq of [68Ga]Ga-DOTAZOL  and  50 MBq of [44Sc]Sc-PSMA-617 was 
calculated by multiplying their mean effective dose (mSv/MBq) with injected 
activities respectively.  
 
2.4.2 Post therapeutic absorbed dose calculation for [177Lu]Lu-DOTAZOL 
and [177Lu]Lu-PSMA-617 by mathematical extrapolation of 
pharmaco-kinetic analysis of [68Ga]Ga-DOTAZOL  and [44Sc]Sc-
PSMA-617 
Total activity of [68Ga]Ga-DOTAZOL and [44Sc]Sc-PSMA-617 in source organs was 
extrapolated to a theoretical [177Lu]Lu-DOTAZOL and [177Lu]Lu -PSMA-617 activity at all 
imaging time points by applying  equation 3-3. 
                           
          
    
           
        -------------------Equation 5 
Where T = physical half-life of 68Ga or 44Sc. In this equation, the physical decay com-
ponent of 68Ga or 44Sc was removed by reverse decay correction to the time of injection 
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leaving only the biological decay component of DOTAZOL or PSMA-617 respectively. By 
applying forward decay correction with the physical half-life of 177Lu (161.52 h) 
theoretical [177Lu]Lu-DOTAZOL and [177Lu]Lu-PSMA-617 kinetics were extrapolated  for 
all imaging time points. In case of whole body activity calculation for [177Lu]Lu-PSMA-
617 above method was applied until the 2 h time point. Then physical decay correction 
for 177Lu was carried forward from 2 h time point. Reason for this was to remove an error 
of increment in activity at the last 19.5 h time point for the whole body activity 
calculation.  Likewise, activity (MBq)/ml data of blood and urine samples were treated in 
the same way as described for source organs as well.   
Organ absorbed doses for [177Lu]Lu-DOTAZOL and [177Lu]Lu-PSMA-617 were 
calculated by using total source organ activity computed by extrapolation following the 
same steps as described for dosimetric analysis of [68Ga]Ga-DOTAZOL and [44Sc]Sc-
PSMA-617. Considering normal tissue complications probability (NTCP) toxicity limits 
derived from external beam radiotherapy (EBRT) for organs at risk, maximum 
permissible activity (Gy) and the  maximum number of therapy cycles of [177Lu]Lu-
DOTAZOL and [177Lu]Lu-PSMA-617 (6 GBq per cycle) that can be administered in each 
patient were determined.  
2.4.3 Dosimetric analysis with [177Lu]Lu-DOTAZOL 
To measure the percent activity in source organs, cumulated activity in source organs 
(kidneys, urinary bladder) was determined. Percent injected activity in skeleton was 
determined by subtraction of percent injected activity in blood, urinary bladder and 
kidneys from percent injected activity in whole body activity. 
 For cumulated activity in source organ, whole body ROI’s were drawn. A 
rectangular ROI was drawn near the head region above the shoulder for background 
measurement and an elliptical ROI was used for measurement of the standard source 
placed between the legs. ROI on adductor muscle was drawn for soft tissue reference. 
Same sized ROI’s were replicated on serial images (kidneys ROI’s up to the 24 h data 
set and all remaining ROI’s in all subsequent image data sets). Background corrected 
counts in right and left kidney, soft tissue, urinary bladder and whole body were 
determined on anterior and posterior images. The geometric mean counts/min in all 
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source organs at all data time points was determined. Using EANM dosimetry committee 
(Hindorf et al., 2005) whole body activity at subsequent time points (T) was determined 
by multiplying the injected activity with the normalized geometric mean whole body 
counts at the respective time points as given in equation 6,  
         
√                                 
√                                 
---------------Equation 6 
where t = 20 min, T= subsequent time points and A0 = initial injected activity. Likewise, 
activity in the urinary bladder was also determined by multiplying the injected activity 
with the normalized geometric mean counts in urinary bladder. 
For calculation of activity in the right and left kidneys at all data points, a conjugate view 
method with a simple geometrically based subtraction technique described in MIRD 
pamphlet no 16 (Siegel and Thomas, 1999) by equation 7 was used,  
    √
    
     
  
 
----------------Equation 7 
where IA = anterior count rate , IP = posterior count rate, fj represents source organ self-
attenuation correction which was calculated from the source region linear attenuation 
coefficient μj and source thickness tj using equation 8. Factor μet represents the 
transmission factor across the patient thickness t in the area of the ROI with a linear 
attenuation coefficient μe calculated using equation 9. From [
68Ga]Ga-DOTAZOL- PET/CT 
of respective patient, CT based measurements of source organ thickness as well as 
whole body thickness and thickness anterior and posterior to source organs at same 
level were used. C is the calibration factor determined for gamma camera with a known 
standard source and was same in all the studies (Siegel and Thomas, 1999). For 
measurements of μj and μi (linear attenuation coefficients for whole thickness), we 
applied a CT based Hounsfield units method described by Kabasakal et al for [177Lu]Lu-
PSMA-617 dosimetric analysis (Kabasakal et al., 2015) 
   
(
    
 
)
     (
    
 
)
----------------Equation 8 
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   ---------------Equation 9 
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A simple geometric based background subtraction technique using equation 10 was 
used, 
   ,*  (
    
  
) (  
  
 
)+ *  (
    
  
) (  
  
 
)+-
 
 
-------------------------Equation 10 
where IADJ is the count rate through the patient from a soft tissue area of same size as 
that of the organ ROI. IA, IP, tj and t are the same a s previously defined (Siegel and 
Thomas, 1999). 
OLINDA/EXM version 2.0 (Hermes Medical Solutions, Stockholm, Sweden) 
software was used for performing bi exponential kinetic analysis on percent injected 
activity in the whole body, kidneys and skeletal system at all data time points and 
calculation of residence times (MBq-h/MBq). Residence time for the skeletal system was 
assumed to be distributed equally between trabecular and cortical bone. Residence time 
for urinary bladder contents was determined by applying Cloutier’s dynamic urinary 
bladder model with 4h voiding interval, total urinary fraction and effective half-life. For 
this urinary fraction at all time points was calculated by applying function A* (1-e- ƛT). 
Effective half-life was determined by fitting a logarithmic function to urinary excretion 
curve. Bone marrow self-dose was determined by using indirect blood-based method 
mentioned earlier. By subtracting residence times for kidneys, bone marrow and skeletal 
system from whole body residence time, the remainder of body residence time was 
calculated. 
Residence time for kidneys, cortical and trabecular bone, urinary bladder 
contents, red marrow self-dose and remainder of body were used as an input in 
OLINDA/EXM version 2.0 (Hermes Medical Solutions, Stockholm, Sweden) software for 
calculation of organ absorbed doses and effective doses after adjusting the weight of 
patient organs as described earlier. 
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3 Results 
The results of visual analysis, biokinetics and dosimetric analysis of three   
radiopharmaceuticals have been found encouraging for their use for diagnosis and 
therapy. The results are summarized below. 
3.1 [68Ga]Ga-DOTAZOL 
3.1.1 Biodistribution and kinetic analysis 
Visual analysis of PET/CT images revealed intense tracer uptake in kidneys, skeleton 
and urinary bladder (illustration 1e). Faint uptake in liver, spleen and salivary glands was 
also seen.  Plotting of % of injected activity in source organs with respect to time 
(illustration 3), highest tracer localization was seen in skeletal system followed by liver, 
kidneys, spleen and salivary glands. In the skeletal target organ, there is an initial rapid 
uptake till 30 min followed by further gradual rise.  Maximum tracer accumulation in 
skeletal system was found to be 18% of injected activity (IA) in one of the bronchial 
carcinoma patients with high burden of skeletal metastases. 
 
ill. 3: Change in % activity of [68Ga]Ga-DOTAZOL in whole skeleton (without decay 
correction) and rest of source organs(without decay correction) and $(estimated initial 
activity) of patient no 2. 
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Fast tracer kinetics through kidneys with early peak uptake in renal parenchyma 
as early as 2.5 min followed by clearance with minimal activity in collecting system at 45 
min p.i. and minimal to no residual activity at 2.5 h p.i. was appreciated both with visual 
analysis (illustration 3) as well as quantitative analysis (illustration 4). Almost 11 % of the 
injected activity remained in whole body at 2.5 h showing 89 % renal excretion. 
 
ill. 4: [68Ga]Ga-DOTAZOL kinetics through kidneys in dynamic (150 s, 450 s, 750 s, 1050 
s, 1350 s, 1650 s) and static images (45 min and 2.5 h). Patient no 3 
Good bone to soft tissue and metastatic lesion to normal bone uptake was visualized at 
45 min p.i.. which increased at 2.5 p.i Further comparison of mean SUV based skeletal 
to soft tissue ratio was found to be 7.36 and 12.96 at 45 min p.i. (illustration 5b) that 
increased to 15.03 and 28.82 at 2.5 h p.i. (illustration 5c) for two representative lesions 
in comparison to 4.81 and 3.30 on previous [68Ga]Ga-PSMA-617 (illustration 5a) in 
patient with mCRPC. Lesion to normal bone ratio for these lesions was found to be 7.53 
and 12.95 at 45 min and 6.79 and 13.01 at 2.5 h p.i.. on PET/CT images of [68Ga]Ga-
DOTAZOL in comparison to 7.5 and 5.14 respectively on [68Ga]Ga-PSMA-617 image. The 
number of lesions were also found higher on [68Ga]Ga-DOTAZOL  as compared to 
[68Ga]Ga-PSMA-617 in mCRPC patient.  
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ill. 5: Uptake in two metastatic lesions on (a) [68Ga]Ga-PSMA-617, (b) [68Ga]Ga-
DOTAZOL at 45 min p.i.. and (c) [68Ga]Ga-DOTAZOL at 2.5 h p.i.. showing higher and 
progressive uptake  with [68Ga]Ga-DOTAZOL as a result of  enhanced lesion to normal 
bone uptake. Patient no 1 
Uptake in lesions and the apparent number of lesions were also found higher on 
visual comparison of [68Ga]Ga-DOTAZOL  with [18F]FDG  in bronchial carcinoma patients 
(illustration 6) and [99mTc]Tc-MDP bone scan in the female patient (illustration 7). SUV 
max in lesion was also found higher on [68Ga]Ga-DOTAZOL (15.24 g/ml) as compared to 
[18F]FDG PET/CT images (5.95 g/ml) in bronchial carcinoma patients. 
 
 
 
 
 
 
 
ill. 6: Comparison of PET/CT images of (a) [68Ga]Ga-DOTAZOL with (b) [18F]FDG in 
patient of skeletal metastases secondary to bronchial carcinoma. Patient no 4 
a b c 
        
a b 
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ill 7: Comparison of [99mTc]Tc-MDP with [68Ga]Ga-DOTAZOL in patient of skeletal 
metastases secondary to breast carcinoma. Patient no 3 
 
3.1.2 Dosimetric analysis for normal organs 
Residence times (MBq-h/MBq) for source organs (table 8) were found highest for 
remainder of body followed by urinary bladder, cortical and trabecular bone, liver, red 
marrow, kidneys, spleen and salivary glands.  
Organs PT 1 PT 2 PT 3 PT 4 PT 5 mean  ± SD 
S. glands 0.004 0.002 0.001 0.001 0.001 0.002 0.001 
Kidney 0.024 0.024 0.020 0.018 0.016 0.021 0.003 
Spleen  0.005 0.004 0.008 0.004 0.006 0.005 0.001 
Liver 0.057 0.034 0.052 0.028 0.032 0.040 0.012 
Red marrow 0.034 0.038 0.053 0.039 0.058 0.042 0.009 
Trabecular bone 0.148 0.117 0.116 0.225 0.150 0.127 0.041 
Cortical bone 0.148 0.117 0.116 0.225 0.150 0.127 0.041 
Urinary bladder 0.172 0.191 0.160 0.534 0.496 0.174 0.177 
Remainder of 
body 0.392 0.468 0.213 0.251 0.377 0.358 0.095 
Table 8: Residence time (MBq-h/MBq) in source organs with [68Ga]Ga-DOTAZOL 
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Organ absorbed doses as well as effective dose according to ICRP103 (table 9) 
clearly describe that the urinary bladder was the critical organ as it received the highest 
absorbed dose of 0.368 mSv/MBq (range: 0.203-0.609 mSv/MBq) as kidneys were 
found to be the only route of its excretion. Osteogenic cells received dose of 0.040 mSv/ 
MBq followed by kidneys (0.031 mSv/MBq), red marrow (0.027 mSv/MBq), spleen 
(0.018 mSv/MBq), liver (0.013 mSv/ MBq) and salivary glands (0.011 mSv/MBq). 
Effective dose was calculated to be 2.61mSv from 150 MBq injected dose. 
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  PT 1 PT 2 PT 3 PT4 PT5 Mean SD  
Organs 
       Adrenals 0.009 0.007 0.010 0.006 0.007 0.008 0.002 
Brain 0.004 0.002 0.003 0.003 0.004 0.003 0.001 
Breast 
  
0.003 
  
0.003 
 Esophagus 0.005 0.002 0.004 0.003 0.004 0.004 0.001 
Eyes 0.004 0.002 0.003 0.003 0.004 0.003 0.001 
Gall bladder 
wall 0.007 0.004 0.005 0.004 0.005 0.005 0.001 
Left colon 0.005 0.003 0.005 0.004 0.005 0.004 0.001 
Small intestine 0.006 0.003 0.005 0.006 0.007 0.005 0.001 
Stomach wall 0.005 0.002 0.004 0.003 0.004 0.004 0.001 
Right colon 0.005 0.003 0.004 0.004 0.005 0.004 0.001 
Rectum 0.008 0.006 0.011 0.013 0.014 0.011 0.003 
Heart Wall 0.005 0.002 0.003 0.003 0.004 0.004 0.001 
Kidneys 0.037 0.037 0.035 0.025 0.024 0.031 0.007 
Liver 0.018 0.011 0.020 0.008 0.010 0.013 0.005 
Lungs 0.005 0.002 0.004 0.003 0.004 0.003 0.001 
Ovaries 
  
0.007 
  
0.007 
 Pancreas 0.005 0.003 0.005 0.003 0.005 0.004 0.001 
Prostate 0.010 0.008 
 
0.017 0.018 0.009 0.001 
Salivary glands 0.022 0.011 0.007 0.005 0.007 0.010 0.007 
Red marrow 0.027 0.022 0.030 0.029 0.028 0.027 0.003 
Osteogenic 
cells 0.042 0.034 0.035 0.049 0.041 0.040 0.006 
Spleen 0.017 0.013 0.029 0.013 0.018 0.018 0.007 
Testes 0.005 0.003 
 
0.006 0.007 0.004 0.001 
Thymus 0.004 0.002 0.003 0.003 0.004 0.003 0.001 
Thyroid 0.004 0.002 0.003 0.003 0.004 0.003 0.001 
Urinary bladder 
wall 0.203 0.222 0.235 0.609 0.572 0.368 0.204 
Uterus 
  
0.011 
  
0.011 
 Total Body 0.008 0.006 0.008 0.007 0.007 0.007 0.001 
Effective dose 
from 150 MBq 2.61 mSv 
Table 9: Organ absorbed doses (mSv/MBq) and effective dose (mSv) from [68Ga]Ga-
DOTAZOL 
3.2 [177Lu]Lu-DOTAZOL 
3.2.1 Qualitative analysis 
Analysis of biodistribution of [177Lu]Lu-DOTAZOL in serial images of two patients of 
bronchial carcinoma and two patients of prostate carcinoma with skeletal metastases  
revealed that at 20 min p.i. most of the activity was in soft tissue with  highest uptake in 
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urinary bladder  followed by kidneys with minimal accumulation in the skeleton. The 
kidneys showed a rapid decrease in activity at 3 h with minimum to no uptake after 24 h 
p.i. along with increasing intense uptake in the skeletal system from 3 h onwards. Blood 
and soft tissue clearance and lesion to normal bone contrast increased in later images 
up to 168 h.  In this small patient study, we observed fast uptake and clearance kinetics 
of kidneys in patients with bronchial carcinoma (illustration 1a-d) as compared to 
mCRPC patient (illustration 8), which resulted in better skeletal to soft tissue contrast as 
early as 3 h p.i. in the bronchial carcinoma patient as compared to 24 h p.i. in mCRPC 
patient.  
 
ill. 8: Planar scintigraphy (anterior and posterior views) after therapeutic application of 
[177Lu]Lu-DOTAZOL at (a) 20 min, (b) 3 h, (c) 24 h, (d) 168 h in a patient with bone 
metastases secondary to prostate cancer (patient no 1) 
 
3.2.2 Dosimetric analysis: 
Mean residence times (MBq-h/MBq) (Table 10) was found to be highest in 
trabecular and cortical bone (31.9 h) followed by remainder of the body (11.7 h), kidneys 
(1.84 h), urinary bladder (1.52 h) and bone marrow (0.03 h). In patient no 1, residence 
times for the skeletal system and the kidney were lower as compared to the other 
patients.  
 
  44  
 
  [¹⁷⁷Lu]Lu-DOTAᶻᴼᴸ 
Organs PT1 PT2 PT3 PT4 mean ± SD 
Kidneys 0.96 2.01 2.43 1.96 1.84 0.63 
Trabecular 
bone 27.45 34.95 33.45 31.85 31.93 3.24 
Cortical bone 27.45 34.95 33.45 31.85 31.93 3.24 
Red marrow 0.01 0.03 0.04 0.03 0.03 0.01 
Urinary 
bladder 
contents 1.59 1.48 1.51 1.50 1.52 0.05 
Remainder of 
body 0.23 44.06 0.93 1.40 11.65 21.61 
Whole body 56.10 116.00 70.30 67.10 77.38 26.46 
Table 10: Residence times (MBq-h/MBq) of [177 Lu]Lu-DOTAZOL 
Mean organ absorbed doses (Table 11) were found highest (3.33 ± 0.35 
mSv/MBq) for osteogenic cells, followed by kidneys (0.49 ± 0.16 mSv/MBq), red marrow 
(0.461 ± 0.064 mSv/MBq) and urinary bladder wall (0.322 ± 0.022 mSv/MBq). Kidney 
and osteogenic cell absorbed doses were lowest in patient no 1. The mean total body 
dose was 0.092 ± 0.033 mSv/MBq. 
 
 
 
 
 
 
 
 
 
 
 
  45  
 
  PT1 PT2 PT3 PT4 mean ±SD 
Organs 
      Adrenals 0.010 0.069 0.016 0.015 0.027 0.028 
Brain 0.007 0.061 0.009 0.009 0.021 0.027 
Esophagus 0.004 0.060 0.006 0.006 0.019 0.027 
Eyes 0.007 0.061 0.009 0.009 0.021 0.027 
Gall bladder wall 0.003 0.060 0.005 0.005 0.018 0.028 
Left colon 0.005 0.062 0.007 0.007 0.020 0.028 
Small intestine 0.004 0.061 0.006 0.006 0.019 0.028 
Stomach wall 0.003 0.058 0.004 0.004 0.017 0.027 
Right colon 0.003 0.060 0.005 0.005 0.018 0.028 
Rectum 0.006 0.062 0.007 0.007 0.021 0.028 
Heart wall 0.003 0.059 0.005 0.005 0.018 0.027 
Kidneys 0.263 0.555 0.632 0.511 0.490 0.160 
Liver 0.003 0.059 0.005 0.005 0.018 0.027 
Lungs 0.004 0.059 0.005 0.006 0.019 0.027 
Pancreas 0.004 0.061 0.006 0.006 0.019 0.028 
Prostate 0.005 0.060 0.006 0.006 0.019 0.027 
Salivary glands 0.004 0.060 0.006 0.006 0.019 0.027 
Red marrow 0.402 0.551 0.456 0.434 0.461 0.064 
Osteogenic cells 2.940 3.770 3.330 3.170 3.300 0.350 
Spleen 0.004 0.060 0.006 0.006 0.019 0.027 
Testes 0.003 0.057 0.004 0.004 0.017 0.027 
Thymus 0.003 0.058 0.004 0.005 0.017 0.027 
Thyroid 0.004 0.060 0.006 0.006 0.019 0.027 
Urinary bladder 
wall 0.333 0.364 0.316 0.316 0.332 0.023 
Total body 0.069 0.142 0.081 0.077 0.092 0.034 
Table 11: Organ absorbed doses (mSv/MBq) of [177Lu]Lu-DOTAZOL 
 
3.3 Post-therapeutic organ absorbed doses for [177Lu]Lu-DOTAZOL 
derived from mathematical extrapolation of [68Ga]Ga-DOTAZOL 
Pharmacokinetics 
Residence times (table 12) from integration of source organ activities obtained from 
mathematical extrapolation of [68Ga]Ga-DOTAZOL data for [177Lu]Lu-DOTAZOL  are given 
below. Residence times for all source organs were found to be low as compared to 
same calculated from therapeutic doses of [177Lu]Lu-DOTAZOL mentioned above. 
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Organs PT1 PT2 PT3 PT4 PT 5 mean ± SD 
Kidneys 0.06 0.04 0.05 0.04 0.04 0.05 0.01 
Trabecular 
bone 0.29 1.77 0.26 22.40 19.00 8.74 11.00 
Cortical 
bone 0.29 1.77 0.26 22.40 19.00 8.75 11.00 
Red marrow 0.33 0.28 0.16 3.17 0.25 0.84 1.30 
Urinary 
bladder 
contents 0.48 1.48 1.06 4.44 15.10 4.51 6.11 
Remainder  
of Body 69.63 56.00 56.00 22.50 54.00 51.63 17.44 
Table 12:  Residence times for [177Lu]Lu-DOTAZOL computed from [68Ga]Ga-DOTAZOL 
The organ absorbed doses for post [177Lu]Lu-DOTAZOL therapy from extrapolation 
of pharmacokinetic analysis of [68Ga]Ga-DOTAZOL  (table 13) showed that osteogenic 
cells with 1.037 mSv/MBq received highest absorbed dose followed by urinary bladder 
(1.021 mSv/MBq) and bone marrow (0.238 mSv/MBq). Kidneys absorbed dose was 
found to be 0.020 mSv/MBq). As compared to the organ absorbed doses determined 
with therapeutic doses of [177Lu]Lu-DOTAZOL, it was clearly seen that pre-therapeutic 
dosimetric analysis with [68Ga]Ga-DOTAZOL computed lower organ absorbed doses. 
Moreover, similar to post [177Lu]Lu-DOTAZOL therapy dosimetric analysis, osteogenic 
cells received highest absorbed dose however the computed values was  three times 
less. Moreover red marrow and kidney doses were found two times and 24 times lower 
with [68Ga]Ga-DOTAZOL extrapolation.  
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  PT1 PT2 PT3 PT4 PT5 mean ±SD 
Organs 
       Adrenals 0.090 0.072 0.089 0.035 0.073 0.072 0.022 
Brain 0.088 0.071 0.086 0.034 0.073 0.070 0.022 
   
0.085 
    Esophagus 0.089 0.072 0.086 0.033 0.072 0.070 0.023 
Eyes 0.088 0.071 0.086 0.034 0.073 0.070 0.022 
Gall bladder 
wall 0.090 0.073 0.090 0.032 0.072 0.071 0.024 
Left colon 0.092 0.074 0.090 0.034 0.075 0.073 0.023 
Small intestine 0.092 0.074 0.089 0.034 0.077 0.073 0.023 
Stomach wall 0.090 0.073 0.089 0.031 0.072 0.071 0.024 
Right colon 0.092 0.074 0.090 0.033 0.074 0.072 0.024 
Rectum 0.092 0.075 0.092 0.038 0.088 0.077 0.023 
Heart Wall 0.091 0.073 0.089 0.032 0.072 0.071 0.024 
Kidneys 0.024 0.016 0.024 0.017 0.020 0.020 0.004 
Liver 0.021 0.021 0.078 0.015 0.014 0.030 0.027 
Lungs 0.089 0.072 0.088 0.032 0.072 0.071 0.023 
Pancreas 0.092 0.074 0.091 0.033 0.074 0.073 0.024 
Prostate 0.092 0.075 0.090 0.037 0.092 0.077 0.023 
Salivary glands 0.186 0.141 0.082 0.043 0.086 0.108 0.056 
Red marrow 0.171 0.093 0.080 0.493 0.353 0.238 0.179 
Osteogenic 
cells 0.128 0.241 0.074 2.580 2.160 1.037 1.228 
Spleen 0.024 0.017 0.028 0.015 0.023 0.021 0.005 
Testes 0.089 0.072 
 
0.032 0.075 0.067 0.024 
Thymus 0.090 0.072 0.088 0.031 0.071 0.071 0.023 
Thyroid 0.090 0.072 0.086 0.033 0.072 0.071 0.023 
Urinary bladder 
wall 0.189 0.374 0.376 0.955 3.210 1.021 1.257 
   
0.092 
    Total Body 0.094 0.079 0.091 0.096 0.137 0.099 0.022 
Table 13: Post therapeutic organ absorbed doses for [177Lu]Lu-DOTAZOL computed from 
[68Ga]Ga-DOTAZOL 
3.4 [44Sc]Sc-PSMA-617:  
3.4.1 Qualitative [44Sc]Sc-PSMA-617 Distribution and Kinetics 
Initial 30 min dynamic abdominal and three serial whole body PET/CT images 
(illustration 2) of patients administered with  [44Sc]Sc-PSMA-617 showed its physio-
logical uptake in kidneys, liver, spleen, salivary glands, small intestine and urinary 
bladder which were selected as source organs for further dosimetric analysis. Very faint 
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uptake was also noticed in lacrimal glands with faint to absent uptake in nasal or oral 
mucosa.  Pathological uptake was also observed in metastatic bone and soft tissue. 
Rapid blood clearance and excretion from kidneys created better tumor to soft tissue 
contrast. 
Plotting % injected activity in source organs with time (illustration 9) revealed 
peak uptake in all source organs achieved before 1 h. Highest % injected activity was 
seen in liver followed by kidneys, spleen, salivary glands and small intestine. Rapid fall 
in activity in liver and other source organs was observed. The decrement in kidneys, 
small intestine and salivary glands was gradual with exception of increase in activity at 2 
h in salivary glands and small intestine in only one patient.  
 
:  
ill. 9: Time dependent changes of % injected activity in source organs 
3.4.2 Dosimetry for Normal Organs 
Residence times (MBq-h/MBq) of [44Sc]Sc-PSMA-617 in source organs was 
highest in liver followed by kidneys, urinary bladder, bone marrow and rest of organs 
(table14) 
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PT No PT1 PT2 PT3 PT4 PT5 mean ±SD 
Organs 
 
            
Salivary glands 0.02 0.01 0.01 0.03 0.07 0.03 0.027 
Kidneys 0.22 0.36 0.12 0.34 0.15 0.24 0.109 
Liver 0.25 0.78 0.07 0.29 0.37 0.35 0.263 
Spleen 0.08 0.09 0.02 0.05 0.09 0.07 0.031 
Small intestine 0.02 0.04 0.02 0.07 0.08 0.05 0.029 
Bone marrow 0.06 0.10 0.05 0.09 0.17 0.09 0.047 
Urinary bladder 
contents 0.08 0.14 0.12 0.53 0.05 0.18 0.195 
Remainder of 
body 2.93 1.11 1.45 1.86 1.76 1.82 0.684 
Table 14: Residence times (MBq-h/MBq) of [44Sc]Sc-PSMA-617 in source organs 
 Mean organ absorbed dose (mSv/ MBq) from diagnostic dose of [44Sc]Sc-PSMA-
617 (table 15) was found highest in the kidneys 0.319 mSv/ MBq (range: 0.180 to 0.488 
mSv/ MBq) making it the critical organ followed by urinary bladder wall, spleen, salivary 
glands, liver and small intestine. Highest dose to kidneys were associated with the fact 
that they are the main route of excretion for PSMA-617. Bone marrow dose was found to 
be low and presented as organs with low toxicity risk while considering therapeutic 
application. 
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  PT 1 PT 2 PT 3 PT4 PT5 Mean ±SD 
Organs 
       Adrenals 0.079 0.112 0.042 0.092 0.056 0.076 0.028 
Brain 0.027 0.011 0.015 0.018 0.015 0.017 0.006 
Esophagus 0.035 0.027 0.019 0.027 0.022 0.026 0.006 
Eyes 0.027 0.011 0.015 0.018 0.015 0.017 0.006 
Gall bladder wall 0.051 0.073 0.024 0.047 0.040 0.047 0.018 
Left colon 0.042 0.030 0.023 0.037 0.027 0.032 0.008 
Small intestine 0.051 0.047 0.032 0.079 0.067 0.055 0.018 
Stomach wall 0.040 0.031 0.021 0.031 0.025 0.030 0.007 
Right colon 0.041 0.033 0.025 0.036 0.026 0.032 0.007 
Rectum 0.038 0.023 0.026 0.048 0.022 0.031 0.011 
Heart Wall 0.037 0.029 0.020 0.028 0.023 0.027 0.007 
Kidneys 0.293 0.488 0.180 0.456 0.178 0.319 0.148 
Liver 0.085 0.229 0.030 0.097 0.095 0.107 0.074 
Lungs 0.033 0.024 0.018 0.025 0.020 0.024 0.006 
Pancreas 0.043 0.037 0.023 0.037 0.029 0.034 0.008 
Prostate 0.040 0.026 0.028 0.057 0.021 0.034 0.014 
Salivary glands 0.097 0.035 0.052 0.116 0.253 0.111 0.086 
Red Marrow 0.036 0.033 0.025 0.037 0.034 0.033 0.005 
Osteogenic cells 0.030 0.023 0.019 0.028 0.026 0.025 0.004 
Spleen 0.235 0.248 0.064 0.163 0.216 0.185 0.075 
Testes 0.030 0.014 0.018 0.027 0.015 0.021 0.007 
Thymus 0.032 0.018 0.018 0.022 0.018 0.022 0.006 
Thyroid 0.031 0.015 0.017 0.021 0.017 0.020 0.006 
Urinary Bladder wall 0.121 0.172 0.155 0.605 0.068 0.224 0.216 
Total Body 0.034 0.023 0.019 0.284 0.020 0.076 0. 116 
Mean effective Dose 0.0389 mSv/MBq 
Effective dose from 50 
MBq 
1.94 mSv 
Effective dose from 62 
MBq 
2.41 mSv 
Table 15: Organ absorbed doses (mSv/MBq) of [44Sc]Sc-PSMA-617 
3.5 Post-therapeutic organ absorbed doses for [177Lu]Lu-PSMA-617 
derived from mathematical extrapolation of [44Sc]Sc-PSMA-617 
Pharmacokinetics 
Extrapolated mean residence times (MBq-h/MBq) of [177Lu]Lu-PSMA-617 (table 
16) were highest in liver (4.46 h) followed by the kidneys (1.51 h), small intestine (0.63 
h), bone marrow (0.52 h), urinary bladder (0.33 h), salivary glands (0.21 h)  and spleen 
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(0.18 h). Residence times in remainder of body showed high variation among patients 
and was found highest in patient 1. 
Patient No PT1 PT2 PT3 PT4 PT5 mean ±SD 
Organs 
       Salivary glands 0.10 0.59 0.24 0.19 0.08 0.24 0.21 
Kidneys 1.07 1.25 1.17 1.96 2.09 1.51 0.48 
Liver 3.48 2.85 3.31 6.18 6.46 4.46 1.72 
Spleen 0.28 0.19 0.09 0.15 0.20 0.18 0.07 
Small Intestine 0.83 0.45 0.71 1.05 0.09 0.63 0.37 
Bone marrow 0.08 0.66 0.06 0.12 1.67 0.52 0.69 
Urinary bladder 
contents 0.23 0.25 0.18 0.90 0.08 0.33 0.32 
Remainder of 
body 64.12 43.72 22.40 44.86 57.80 46.58 16.04 
Table 16: Extrapolated residence times (MBq-h/MBq) of [177Lu]Lu-PSMA-617 
Individual and mean organ absorbed doses of [177Lu]Lu-pSMA-617 extrapolated 
from [44Sc]Sc-PSMA-617 (table 17) revealed kidneys as critical organs with highest 
mean organ absorbed dose (0.44 mSv/MBq), followed by the salivary glands (0.23 
mSv/MBq), liver (0.22 mSv/MBq), small intestine (0.14 mSv/MBq), spleen and urinary 
bladder wall with 0.12 mSv/MBq each. Mean bone marrow absorbed dose was found to 
be 0.05 mSv/MBq and mean whole body dose was 0.08 mSv/MBq.  
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Patient  No PT 1 PT 2 PT 3 PT4 PT5 Mean ±SD  
Organs 
       Adrenals 0.04 0.06 0.04 0.07 0.06 0.05 0.01 
Brain 0.08 0.05 0.03 0.05 0.05 0.05 0.02 
Esophagus 0.10 0.05 0.03 0.05 0.05 0.06 0.02 
Eyes 0.08 0.05 0.03 0.05 0.05 0.05 0.02 
Gall bladder wall 0.13 0.06 0.04 0.06 0.06 0.07 0.03 
Left colon 0.13 0.05 0.03 0.06 0.06 0.07 0.04 
Small intestine 0.20 0.11 0.12 0.19 0.07 0.14 0.06 
Stomach wall 0.12 0.05 0.03 0.06 0.05 0.06 0.03 
Right colon 0.10 0.05 0.03 0.06 0.06 0.06 0.03 
Rectum 0.08 0.05 0.03 0.06 0.05 0.06 0.02 
Heart Wall 0.09 0.05 0.03 0.06 0.06 0.06 0.02 
Kidneys 0.54 0.33 0.34 0.52 0.47 0.44 0.10 
Liver 0.24 0.14 0.17 0.29 0.26 0.22 0.06 
Lungs 0.09 0.05 0.03 0.05 0.05 0.06 0.02 
Pancreas 0.13 0.05 0.03 0.06 0.06 0.07 0.04 
Prostate 0.08 0.05 0.03 0.06 0.05 0.06 0.02 
Salivary glands 0.11 0.55 0.25 0.18 0.07 0.23 0.19 
Red Marrow 0.07 0.06 0.03 0.04 0.04 0.05 0.02 
Osteogenic cells 0.06 0.04 0.02 0.03 0.03 0.04 0.02 
Spleen 0.26 0.11 0.06 0.09 0.10 0.12 0.08 
Testes 0.08 0.05 0.03 0.05 0.05 0.05 0.02 
Thymus 0.08 0.05 0.03 0.05 0.05 0.05 0.02 
Thyroid 0.08 0.05 0.03 0.05 0.05 0.05 0.02 
Urinary Bladder 
wall 0.13 0.10 0.07 0.24 0.07 0.12 0.07 
Total Body 0.17 0.06 0.04 0.06 0.06 0.08 0.05 
Table 17: Extrapolated organ absorbed doses of [177Lu]Lu-PSMA-617 
In order to calculate maximum permissible activity of [177Lu]Lu-PSMA-617 (table 
18) that can be administered in each patient with respect to dose limits derived from 
external beam radiotherapy(EBRT) i.e. kidneys (23 Gy), bone marrow(2 Gy), whole 
body(2 Gy), salivary glands(25 Gy), liver(30 Gy), small intestine(40 Gy) and urinary 
bladder(60 Gy), normal tissue dose limit of these organs was divided by corresponding 
organ absorbed doses in each patient. 
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Patient  No PT 1 PT 2 PT 3 PT4 PT5 Mean 
Organs 
      Small intestine 198.02 366.97 336.13 216.22 611.62 285.00 
Kidneys 42.36 68.86 67.65 44.06 49.15 52.11 
Liver 126.58 220.59 176.47 103.09 117.19 137.61 
Salivary glands 235.85 45.45 102.04 136.61 379.64 108.71 
Red Marrow 29.07 32.52 74.07 46.95 56.66 42.52 
Urinary Bladder 
wall 472.44 576.92 874.64 250.00 865.80 492.69 
Total Body 11.76 34.60 54.20 31.55 33.22 25.75 
Table 18: Predicted maximum feasible activity (GBq) in individual patients considering 
toxicity limits for organs with EBRT 
In patient 1 and 2, maximum permissible activity was determined by the red 
marrow absorbed dose and in patient 3, 4 and 5 the kidney absorbed dose was the 
limiting factor. In case of patient 1, renal dose was also high, resulting in a high 
cumulative dose to the whole body further limiting the maximum permissible activity. 
Toxicity limits for the salivary glands, small intestine and urinary bladder were found to 
exert no influence in this context.  
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4 Discussion 
With rapid advancements in development of new radiopharmaceuticals, nuclear 
medicine has evolved from imaging of biological targets to targeted drug delivery against 
these specific targets. The combined use of radiopharmaceuticals designed for same 
molecular target for diagnosis and treatment with aim of patient-specific treatment has 
introduced concept of theranostics and personalized medicine in nuclear medicine. 
Radiation dosimetric analysis is an important aspect of theranostics that assesses safety 
and efficacy of radionuclide therapy as well as the safety of diagnostic 
radiopharmaceutical used as counter-part. At present, the most successful groups of 
isotopes for theranostics are 123I/124/I/ 131I, 68Ga/177Lu and 111In/86Y/90Y (Eberlein et al., 
2017).   
Several studies advocate that theranostic concept can be utilized for prediction of 
absorbed doses for therapeutic radionuclide. 124/I/ 131I pair has been successfully applied 
with this intent in differentiated thyroid carcinoma and prostate carcinoma ( Erdi et al., 
1999; Zechmann et al., 2014). Many new compounds other than octreotides e.g., PSMA, 
bisphosphonates, bombesin analogues have been labeled with 68Ga for PET/ CT 
imaging and 177Lu for therapy. Besides having different chemistry, the supposedly 
similar pharmacology has established use of 68Ga labeled compounds for diagnosis and 
follow-up of disease. However, the theranostic use of short lived 68Ga labeled 
compounds for prediction of absorbed doses for 177Lu labeled compounds need to be 
assessed. The comparison of hypothetical uptake kinetics of 68Ga with 177Lu showed 
that it only covers the very early phase of pharmacology of analogue compound (Rösch 
et al., 2017) thus questioning its potential to assess accurate biokinetics and related 
areas under the time-activity curves for normal organs and tumor lesions. As physical 
half-life of diagnostic radionuclide seems to be an important consideration in predictive 
theranostic capability interest is geared for PET radionuclides with long half-life such as 
44Sc having half-life of 3.9 h to determine uptake kinetics for structurally similar 177Lu 
labeled therapeutic compounds. 
MIRD schema proposed by Medical Internal Radiation Dose (MIRD) committee of 
the Society of Nuclear Medicine provides the guidelines for appropriate data selection 
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for kinetic analysis of radionuclides used for diagnostic as well as therapeutic purposes. 
The MIRD formula to be applied at organ and voxel level for normal organs and tumor 
lesions respectively has been extensively explained in MIRD pamphlet no 21 and 17 
respectively. The advancement in radiation dosimetric analysis of radionuclides 
suggests use of normal tissue complications probability (NCTP) and tumor control 
probability (TCP) in correlation with dose volume histograms for normal organs and 
tumor lesions for optimal treatment dose determination.  
In this research work we have evaluated biodistribution and safety of [68Ga]Ga-
DOTAZOL and [177Lu]Lu-DOTAZOL as new theranostic bisphosphonates for metastatic 
skeletal disease along with  predictive theranostic potential of [68Ga]Ga-DOTAZOL for  
[177Lu]Lu-DOTAZOL. Also in view of better potential of 44Sc with long half-life for 
theranostics, biodistribution, dosimetric analysis and of [44Sc]Sc-PSMA-617 as new 
diagnostic radionuclide for mCRPC patients along with determination of post therapeutic 
absorbed doses for [177Lu]Lu-PSMA-617 from  its pharmacokinetic analysis has been 
assessed. The three radiopharmaceuticals are discussed one by one 
4.1 Biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL 
Bisphosphonates are analogues of naturally occurring pyrophosphates that are 
resistant to chemical or enzymatic hydrolysis. Their antiresorptive effect is mediated by 
high affinity for bone mineral and inhibitory effects on osteoclasts. Since long, 
radiolabeled bisphosphonates have been in use for imaging and bone pain palliation of 
metastatic skeletal disease. Use of macro cyclic chelators DOTA and NOTA for labeling 
bisphosphonates with trivalent metals like 68Ga for diagnosis and 177Lu for therapy 
resulted in development of labeled BPAPD, DOTAZOL and NO2APBP respectively. 
Among these NO2APBP is considered the most potent 68Ga labeled bisphosphonate. 
However, its therapeutic counter- part labeled with 177Lu was found inferior to [177Lu]Lu-
BPAPD. At present, [68Ga]Ga-NO2APBP and  [177Lu]Lu-BPAMD are considered as 
theranostic pair for bone pain palliation. Preclinical animal and in vitro studies have 
proposed [68Ga]Ga-DOTAZOL in combination with  [177Lu]Lu-DOTAZOL and [225Ac]Ac-
DOTAZOL as new theranostic bisphosphonate for metastatic skeletal disease patients. 
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Hence, necessitates evaluation of biodistribution and dosimetric analysis of [68Ga]Ga-
DOTAZOL. 
The biodistribution and dosimetric analysis of [68Ga]Ga-DOTAZOL was studied for 
first time in humans. The patients of bronchial carcinoma, mCRPC and breast carcinoma 
with metastatic skeletal disease were injected with [68Ga]Ga-DOTAZOL.. Like other bis-
phosphonates and bone seeking agents, kidneys were found to be the route of 
excretion. Fast tracer kinetics through kidneys (illustration 3 and 4) was seen resulting in 
whole body activity to decease to almost 11 % till 2.5 h p.i.. Skeletal system showed 
initial rapid accumulation followed by gradual rise. Initial uptake in liver, spleen and 
salivary glands was also seen followed by sharp decline. 
 Soft tissue and blood activity decreased with time and resulted in enhanced bone 
uptake and increased metastatic lesion to bone ratio (illustration 5) which is consistent 
with results of other 68Ga-bisphosphonate agents and [18F]NaF (Meckel et al, 2017; 
Pfannkuchen et al, 2017). PET/CT images of [68Ga]Ga-DOTAZOL could be compared to 
previous [68Ga]Ga-PSMA-617 and [18F]FDG PET/CT images in the male patients and a 
[99mTc]Tc-MDP bone scan enrolled in this study. Here, the uptake of [68Ga]Ga-DOTAZOL 
was 2.56 times higher than [18F]FDG  in bronchial carcinoma patient . Apparent number 
of lesions were also found more with [68Ga]Ga-DOTAZOL as compared to [68Ga]Ga-
PSMA-617 (illustration 5), [18F]FDG in bronchial carcinoma (illustration. 6) and [99mTc]Tc-
MDP in breast carcinoma patient (illustration 7].  
Compared with [68Ga]Ga-PSMA-617, the qualitative analysis of [68Ga]Ga-DOTAZOL 
showed better uptake in skeleton with higher skeleton to soft tissue and metastatic 
lesion to normal bone ratio (illustration 5). This finding is consistent with in vivo 
biodistribution analysis of [68Ga]Ga-DOTAZOL in one patient of prostate cancer 
(Pfannkuchen et al., 2017).  
As [18F]NaF is the bone seeking radiopharmaceutical with highest sensitivity and 
specificity for metastatic skeletal disease, the dosimetric analysis of [68Ga]Ga-DOTAZOL 
was compared with [18F]NaF. Residence times (table 8) for remainder of body of 
[68Ga]Ga-DOTAZOL (0.358 h) was found comparable to that of [18F]NaF 0.33 reported in 
ICRP 106 report (ICRP, 2008). Urinary bladder residence time (0.174 h) of [68Ga]Ga-
DOTAZOL was found to be less than that of [18F]NaF (0.19 and 0.29 h), however the 
residence time for kidneys was found to be higher (0.022 h) as compared to [18F]NaF 
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(0.01 h). This could be explained by the fact that [68Ga]Ga-DOTAZOL has shown 89 % of 
renal excretion over a period of 2.5 h as compared to 15% and 50% in case of [18F]NaF 
(ICRP, 2008; Kurdziel et al., 2012;) The residence time of [68Ga]Ga-DOTAZOL in 
trabecular and cortical bone was found to be 0.127 with 50 % weightage given to both. 
The residence time in bone components as well as bone marrow were lower as 
compared to [18F]NaF. It might be a result of lower half-life of 68Ga as compared to 18F 
as well as the difference of osteogenic tumor load in patients evaluated by Kurdziel et al 
and the current study. Residence times for liver and spleen were found higher than 
[18F]NaF. The uptake of free/ unbound 68Ga can be responsible for prolonged residence 
times in these organs.  
[68Ga]Ga-DOTAZOL like other bone seeking agents was found to be characterized 
with delivering highest radiation absorbed dose to urinary bladder, followed by 
osteogenic cells, red marrow and kidneys (table 9). This finding is comparable with 
dosimetric analysis of [18F]NaF (ICRP, 2008; Kurdziel et al., 2012). Kidney being its 
physiological route of excretion results in highest dose to urinary bladder. The doses 
delivered to urinary bladder and kidneys were 2.4 times higher and radiation absorbed 
doses to osteogenic tissue and red marrow were lower as compared to [18F]NaF (ICRP, 
2008; Kurdziel et al., 2012). Mean effective dose and total effective dose were found to 
be 0.017 mSv/MBq and 2.61 mSv with [68Ga]Ga-DOTAZOL comparable to 0.017 
mSv/MBq and 1.88 – 3.15mSv with [18F]NaF respectively (ICRP, 2008; Kurdziel et al., 
2012). 
 As described earlier [68Ga]Ga-NO2APBP is considered the most potent 68Ga 
labeled bisphosphonates so dosimetric analysis of [68Ga]Ga-DOTAZOL was compared 
with [68Ga]Ga-NO2APBP (Passah et al., 2017). The comparison revealed high absorbed 
doses delivered to kidneys and urinary bladder, almost comparable absorbed doses to 
bone marrow and osteogenic cells, high total body absorbed dose and high effective 
dose equivalent which illustrates the superiority of [68Ga]Ga-NO2APBP. The difference of 
kidney and urinary bladder absorbed doses could be due to difference of collection of 
data points till 4 h for [68Ga]Ga-NOTAPBP in comparison to 2.5 h in current study. Further 
lack of detailed biodistribution analysis is also a limitation for comparing the results of 
the two studies. It was observed that the dosimetric results of [68Ga]Ga-NO2APBP from 
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breast carcinoma patients (M:F; 1:4) were not comparable to results for the one female 
breast carcinoma patient (Pt 3) of the current study.  
The resultant high urinary bladder and kidney absorbed doses from [68Ga]Ga-
DOTAZOL is consistent with other bone seeking agents. These doses can very easily be 
reduced by proper hydration and rapid diuresis. As compared to various 68Ga labeled 
octreotide (Walker et al., 2013) and PSMA agents (Afshar-Oromieh et al., 2015; 
Herrmann et al., 2015), [68Ga]Ga-DOTAZOL delivered lower kidney and higher urinary 
bladder absorbed doses along with lower mean effective dose.  
Besides having 2.4 times high radiation exposure to kidneys and urinary bladder as 
compared to [18F]NaF, possibility of treatments of bone metastases with [177Lu]Lu-
DOTAZOL and [225Ac]Ac-DOTAZOL gives [68Ga]Ga-DOTAZOL a clear advantage over other 
bone seeking diagnostic agents such as [18F]Na-F and [99mTc]Tc-MDP.  These initial 
results are encouraging and support the use of [68Ga]Ga-DOTAZOL as imaging 
theranostic agent. However, prospective patient studies are required to explore its 
further potential for the treatment of bone metastases in different tumor entities. 
4.2 Biodistribution and dosimetric analysis of [177Lu]Lu-DOTAZOL 
Zoledronate presents as an ideal candidate for labeling with the therapeutic 
radionuclide lutetium-177 for radionuclide therapy of bone metastases, as it shows high 
osteoclast and hydroxyl apatite binding (Meckel et al., 2017) and no in vivo 
biotransformation (Nikzad et al., 2013). Preclinical small animal studies using [177Lu]Lu-
DOTAZOL and [68Ga]Ga-DOTAZOL showed comparable results, suggesting the two 
tracers as new theranostic pair for bone-targeted radionuclide therapy (Meckel et al., 
2017). Moreover, [177Lu]Lu-DOTAZOL has also been proposed the therapeutic arm with 
[68Ga]Ga-NODAGAZOL (suggested better than [68Ga]Ga-DOTAZOL in preclinical studies). 
Hence, biodistribution and dosimetric analysis of [177Lu]Lu-DOTAZOL was explored in 
patients with skeletal metastases. 
Extrapolation of dosimetric analysis of [177Lu]Lu-DOTAZOL and [177Lu]Lu-EDTMP 
from rats to humans revealed high kidney and trabecular bone absorbed doses as well 
as high trabecular bone to other organs absorbed dose ratios for [177Lu]Lu-
DOTAZOL(Yousefnia et al., 2015). The higher thermodynamic and kinetic stability, 
leading to high bone uptake with low soft tissue accumulation, suggests [177Lu]Lu-
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DOTAZOL to be a better therapeutic bisphosphonate compared to [177Lu]Lu-EDTMP 
(Bergmann et al., 2016). 
As phase I and II studies with [177Lu]Lu-EDTMP for bone pain palliation under IAEA 
CRP project have shown encouraging results, therefore we have compared the 
biodistribution and dosimetric analysis of  results of [177Lu]Lu-DOTAZOL with [177Lu]Lu-
EDTMP.  
Biodistribution of [177Lu]Lu-DOTAZOL in humans (illustrations 1a-d & 8) was 
consistent with preclinical biodistribution studies in male Wistar rats (Meckel et al., 2017; 
Yousefnia et al., 2015). Highest accumulation in the skeleton with fast kidney uptake and 
clearance was seen. As the kidneys are the sole route of its excretion, the urinary 
bladder showed high uptake as well. Blood and soft tissue showed rapid clearance 
which resulted in good skeleton to soft tissue contrast. A rapid and biphasic blood 
clearance curve was found comparable to [177Lu]Lu-EDTMP (Bal et al., 2015) . No 
uptake was seen in any other organ. Prominent uptake in the skeletal system in 
bronchial carcinoma patients was visualized at 3 h p.i. image in contrast to 24 h p.i. in 
mCRPC patients. The finding of best bone-to-soft tissue contrast at 24 h p.i. in mCRPC 
patients is consistent with similar observations with [177Lu]Lu-EDTMP distribution in 
mCRPC patients (Bal et al., 2015; Balter et al., 2015; Sharma et al., 2017). To establish 
whether the early uptake in bronchial carcinoma patients is a patient dependent or tumor 
dependent finding and can be of any significance in relation to tumor lesion doses needs 
further large scale and tumor lesion dosimetry studies. 
The source organs identified for dosimetric analysis included the kidneys, bone 
marrow, urinary bladder, skeletal system and the whole body. A biphasic kinetic 
behavior of [177Lu]Lu-DOTAZOL was observed in all source organs and the whole body. 
Hence, biexponential curve fitting was used for residence time calculations. Residence 
time of  [177Lu]Lu-DOTAZOL (table 10) was highest in the skeleton similar to [177Lu]Lu-
EDTMP (Bal et al., 2015). Residence time for all source organs except the kidneys were 
lower in comparison to [177Lu]Lu-EDTMP (Bal et al., 2015). The low number of patients 
and the different methodology used for determination of residence time in our current 
study might be causes for this difference. However, the ratio of skeletal-to-whole body 
residence time was higher for [177Lu]Lu-DOTAZOL compared to [177Lu]Lu-EDTMP (Bal et 
al., 2015). 
  60  
 
We found lower mean organ absorbed doses (table 11) for osteogenic cells (3.33 ± 
0.35 mSv/MBq) compared to 5.41 and 5.26 mSv/MBq reported for [177Lu]Lu-EDTMP 
(illustration 4) (Bal et al., 2015; Sharma et al., 2017) as well as 4.04 mSv/MBq for 
[153Sm]Sm-EDTMP(Sharma et al, 2017). The difference might be due to humerus (Bal et 
al., 2015) or femoral activity (Sharma et al., 2017) extrapolation for skeletal activity and 
residence time calculations for [177Lu]Lu-EDTMP as compared to calculation of skeletal 
activity by deduction of percent kidney, blood and bladder activity from percent whole 
body activity in current study.  
In our study we found a higher mean organ absorbed dose (table 11) for the 
kidneys (0.49 mSv/MBq) as compared to [177Lu]Lu-EDTMP (0.04 and 0.06 mSv/MBq) 
(Bal et al., 2015; Sharma et al., 2017). In contrast to the use of the conjugate view 
method for kidney residence time calculation in our current study, Bal et al.(Bal et al., 
2015) neglected kidney self-dose in absorbed dose determination and Sharma et 
al(Sharma et al., 2017) used a different methodology for calculation of percent injected 
doses in kidneys which resulted in lower kidney dose for [177Lu]Lu-EDTMP. Hence, the 
kidney absorbed doses reported for [177Lu]Lu-EDTMP cannot be compared with the 
results of [177Lu]Lu-DOTAZOL in our current study. The mean organ absorbed dose to the 
urinary bladder wall (0.332 mSv/MBq) was found to be lower in our study as compared 
to [177Lu]Lu-EDTMP (1.53 mSv/MBq) (Bal et al., 2015; Sharma et al., 2017). This 
difference could be due to use of Clouttier´s method with cumulative urinary calculation 
from whole body retention and 4 h voiding intervals in our current study as compared to 
collection of urine samples for residence time calculation in the [177Lu]Lu-EDTMP 
studies.  
[177Lu]Lu-DOTAZOL resulted in a lower bone marrow absorbed dose compared to 
[177Lu]Lu-EDTMP (Bal et al., 2015; Sharma et al., 2017) which in theory allows 
administration of higher therapeutic activities of [177Lu]Lu-DOTAZOL. Based on a 
maximum permissible radiation absorbed dose to the bone marrow of 2Gy, the 
maximum tolerated dose for [177Lu]Lu-DOTAZOL is estimated to be 3630-4980 MBq as 
compared to 2000–3250 MBq for [177Lu]Lu-EDTMP (Bal et al, 2015). As a result, 
radiation absorbed dose of 11 to 16 Gy will be delivered to osteogenic cells by [177Lu]Lu-
DOTAZOL which is comparable to 10.1 to 17.6 Gy for [177Lu]Lu-EDTMP. Using these 
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thresholds, the kidney absorbed dose remains well below the maximum permissible 
dose limit of 23 Gy.  
As absorbed dose to kidneys is one of the important factors in radionuclide 
therapy using Lutetium-177 labeled radiopharmaceuticals, we found that [177Lu]Lu-
DOTAZOL delivers a lower (by a factor of 1.2 to 1.88) kidney dose in comparison to 
[177Lu]Lu-PSMA-617 and [177Lu]Lu-HBED-CC(Kabasakal et al., 2015; Scarpa et al., 
2017). [177Lu]Lu-DOTAZOL has been found to be a promising new therapeutic 
radiopharmaceutical for radionuclide therapy of bone metastases due to excellent 
skeletal uptake, a lower bone marrow dose than [177Lu]Lu-EDTMP and a very low kidney 
dose. Further studies are warranted to evaluate the efficacy and safety of radionuclide 
therapy with [177Lu]Lu-DOTAZOL in the clinical setting. 
4.3 Predictive dosimetry with [68Ga]Ga-DOTAZOL for [177Lu]Lu-DOTAZOL 
The residence times (table 12) and mean organ absorbed doses (table 13) for 
[177Lu]Lu-DOTAZOL determined from extrapolation of pharmacokinetics of [68Ga]Ga-
DOTAZOL were found to be low as compared to same (table 10 and table 11) determined 
from post therapeutic dosimetric analysis of [177Lu]Lu-DOTAZOL. As bone marrow 
absorbed dose appeared to be important for maximum tolerated dose of [177Lu]Lu-
DOTAZOL, it appeared that lower extrapolated bone marrow absorbed dose will result in 
computation of higher therapeutic doses. Moreover, it was seen that individual absorbed 
doses for normal organs in patient no 4 and 5 with bronchial carcinoma were correlating 
better to the post therapeutic absorbed doses as compared to patients of prostate and 
breast carcinoma patient 1,2 and 3 respectively but still presented with lower doses. It 
could be due to individual difference of kinetics in these patients. Thus it is concluded 
that [68Ga]Ga-DOTAZOL should not be used for prospective dosimetric analysis of 
[177Lu]Lu-DOTAZOL. This finding is consistent with the fact that short half-life of 68Ga 
cannot monitor the kinetics of 177Lu (Rösch et al., 2017). 
4.4 Biodistribution and dosimetric analysis of [44Sc]Sc-PSMA-617 
PSMA-617 is a modified version of PSMA-11 that binds to the external domain of 
PSMA. Comparative biodistribution studies with PSMA-11 has revealed supremacy of 
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PSMA-617 due to high target binding and subsequent efficient internalization with in 
prostate carcinoma cells (Afshar-Oromieh et al., 2015). It has been labeled with gallium-
68, lutetium-177, indium-111 and yttrium-90. Although, pre and post [177Lu]Lu-PSMA-
617 therapy, theranostic use of [68Ga]Ga-PSMA-617 for patient selection and disease 
monitoring  is widely used (Afshar-Oromieh et al., 2015; Baum and Kulkarni, 2012), the 
dosimetric analysis results in lower organ absorbed doses as compared to [177Lu]Lu-
PSMA-617. Moreover, it is believed that short half-life (1.13 h) of [68Ga]Ga-PSMA-617 is 
not suitable  to follow the pharmacokinetics of  [177Lu]Lu-PSMA having half-life of 6.9 h 
and cannot be used for prediction of post therapeutic dosimetric analysis of [177Lu]Lu-
PSMA and personalized dose determination.  
Recently PSMA-617 has been labeled with long lived PET agents like scandium-44 
using DOTA as a linking chelator. Preclinical (in vitro, in vivo) and clinical studies with 
scandium-44 labeled peptides and PSMA ligand for neuroendocrine tumors (Singh et al., 
2017) and prostate carcinoma (Umbricht et al., 2017) respectively have proposed 
scandium-44 a better surrogate marker for lutetium-177 based therapies and probable 
better candidate for pre-therapeutic dosimetric analysis. In this study we evaluated its 
feasibility as new imaging theranostic radionuclide in mCRPC patients. 
In this study we found the physiological uptake of [44Sc]Sc-PSMA-617 in liver, 
kidneys, salivary glands, spleen, small intestine, urinary bladder (illustration 2 and 9) 
consistent with low level uptake in normal organs of PSMA described in literature 
(Afshar-Oromieh et al., 2013, 2015). Pathological uptake was seen in both skeletal and 
soft metastatic tissue. Kidneys were the major route of excretion with rapid peak uptake 
seen at 45 min and fast clearance showing minimal activity at 18 h concurrent with early 
uptake and fast clearance characteristic of PSMA-617. Probable toxicity of salivary 
glands proposed by A Afshar- Oromieh  et al  due to late trapping of [68Ga]Ga-PSMA-
617 in salivary glands was not observed  in this study (Afshar-Oromieh et al., 2015). 
Increase in activity in 2 h image was observed in only one of the patients which later 
decreased to minimal activity at 19.5 h while rest of the patients showed peak uptake at 
45 min followed by gradual decrease. The low probability of salivary gland toxicity 
depicted by kinetics of [44Sc]Sc-PSMA-617 is consistent with dosimetry results of 
[68Ga]Ga-PSMA-617(Afshar-Oromieh et al., 2015). Occurrence of transient xerostomia 
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or mild reversible xerostomia with [177Lu]Lu-PSMA-617  as well as other lutetium-177 
labeled PSMA therapies also supports that salivary glands toxicity should be of less 
concern in these patients (Ahmadzadehfar et al, 2016; Baum et al, 2016; Rahbar et al, 
2016a, 2016b). Lacrimal glands showed faint uptake with no enhanced accumulation in 
later images, therefore we considered its activity with in remainder of body activity. Faint 
to negligible uptake in nasal mucosa was seen with [44Sc]Sc-PSMA-617. The rapid initial 
uptake in liver and spleen followed by fast clearance as result of blood pool effect and its 
clearance from these organs is consistent with literature (Afshar-Oromieh et al., 2015)  
Quantitative analysis revealed high total activity (illustration 9) and prolonged 
residence time in liver (table 14) followed by kidneys, spleen and other organs 
consistent with results of [68Ga]Ga-PSMA-617 (Afshar-Oromieh et al., 2015). Residence 
time of source organs with [44Sc]Sc-PSMA-617 were found to be higher than [68Ga]Ga-
PSMA-617. Long half-life of 3.9 h and ability to follow bio kinetics up to 19.5 h or more 
with [44Sc]Sc-PSMA-617 account for the higher residence times as compared to 
[68Ga]Ga-PSMA-617.   
The organ absorbed doses (table 15) were highest in kidneys followed by urinary 
bladder wall, spleen, salivary glands, liver and small intestine. Kidneys with mean dose 
of 0.319 mSv/MBq (range: 0.178-0.488 mSv/MBq) were the organs at risk as is with the 
rest of small ligands based PSMA agents (Afshar-Oromieh et al., 2015). Urinary bladder 
wall with mean dose of 0.224 mSv/MBq was the second highest organ to receive dose 
owing to the kidneys being its physiological route of excretion. Salivary glands received 
a dose of 0.111 mSv/MBq which was higher than [68Ga]Ga-PSMA-I&T but was not 
reported with [68Ga]Ga-PSMA-617 besides showing a rise in mean SUV at later time 
points (Afshar-Oromieh et al., 2015). Bone marrow dose was found to be low consistent 
with previous dosimetric studies with gallium-68 labeled agents. Mean organ absorbed 
dose for bone marrow was found to be 0.033 mSv/MBq and ranged from 0.025 to 0.037. 
Low marrow dose suggests low risk of marrow toxicity with PSMA based therapies. 
However, the marrow toxicity can vary with burden of bone and marrow metastases in 
the patient as was found to be highest in patient no 1 with high tumor burden. Further, 
our results are concurrent with that of [68Ga]Ga-PSMA-617 ,[68Ga]Ga-PSMA-11 and 
[68Ga]Ga-PSMA-HBED-CC with reference to high to low dose received by organs. 
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However, absorbed doses were found to be higher for [44Sc]Sc-PSMA-617 than 
[68Ga]Ga-PSMA-617, [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA-I&T but less than [124I]I-
PSMA (Pfob et al., 2016). 
Comparison of organ absorbed doses of [44Sc]Sc-PSMA-617 with pre and post 
therapeutic dosimetric results of [177Lu]Lu-PSMA-617(Delker et al, 2016; Kabasakal et 
al., 2015; Okamoto et al., 2017) and comparison of doses with other gallium labeled 
PSMA agents also show that it is able to predict doses better than [68Ga]Ga-PSMA-
617(Afshar-Oromieh et al., 2013, 2015). However interpatient dosimetric comparison 
studies of [44Sc]Sc-PSMA-617 with [177Lu]Lu-PSMA-617 are warranted.  
The mean effective dose of 0.0398 was found to be higher than [68Ga]Ga-PSMA-
617, [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA-I&T but less than [124I]I-PSMA (Pfob et al., 
2016). The total effective dose with usual dose administered (50MBq) of [44SSc]Sc-
PSMA-617 was found to be 1.95mSv which was low as compared to rest of gallium-68 
labeled PSMA agents as well [124I]I-PSMA.  
Hence [44SSc]Sc-PSMA-617 having possibility of delayed imaging, higher organ 
absorbed doses and effective dose less than other PSMA labeled imaging agents and a 
similar biodistribution to already known 68Ga-PSMA ligands could be a better and safe 
agent for prediction of therapeutic dosimetry for [177Lu]Lu-PSMA-617. The biodistribution 
and dosimetric analysis in this study has proved that early uptake kinetics reaching peak 
followed by clearance of PSMA-617 from source organs up to 19.5 h can easily be 
interpreted. A comparison of [44SSc]Sc-PSMA-617 kinetics of our study with kinetics of 
[177Lu]Lu-PSMA-617 shown by Delker et al (Delker et al., 2016)  as well as in vivo 
kinetics of [177Lu]Lu-PSMA-617 in pre-clinical small animal studies followed for 24 h 
(Benešová et al., 2015) has shown comparable biodistribution with peak uptake as early 
as 1 h followed by gradual clearance till 24 h. Moreover, the protocol can be completed 
within 24 hours and most important of all can be incorporated in daily clinical routine. It is 
important to mention that individual pre-therapeutic dosimetric analysis with [44Sc]Sc-
PSMA-617 is not necessary for all patients, but for patients not responding to standard 
doses or having a high cumulative dose or having reduced renal function in the lab. 
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4.5 Predictive dosimetry with [44Sc]Sc-PSMA-617 for [177Lu]Lu-PSMA-
617 
The mean ± SD of extrapolated residence time (table 16) for [177Lu]Lu-PSMA-617 
for the remainder of the body in our study was 46.58 ±16.04 h (range: 22.4 -64.12 h), 
which is in line with  the results of the study of L. Kabasakal et al, (mean ± SD 37.9 ± 
14.6 h ; range: 24.6 – 62.0 h). We also observed that patient 1, who had renal 
insufficiency as well as extensive bone metastasis, exhibited the longest residence time, 
which is consistent with the observations of L. Kabasakal et al (Kabasakal et al, 2015). 
The extrapolated mean organ absorbed doses for [177  Lu]Lu-PSMA-617in our study 
were comparable with other pre-therapeutic and post-therapeutic dosimetry results 
obtained with [177Lu]Lu-PSMA-617 (Delker et al., 2016; Fendler et al., 2017; Kabasakal 
et al., 2015;  Kratochwil et al., 2016; Kulkarni et al., 2016; Okamoto et al., 2017). 
However, we observed a lower mean absorbed dose in the kidneys, compared to 
previous studies. This might be explained by the analysis of 3D PET/CT activity 
distribution in the kidneys, as compared to 2D planar gamma camera-based distribution 
measurement, which has inherent potential of over-estimation of kidney dose owing to 
activity contribution from overlapping organs. On the other hand, we observed a higher 
mean organ absorbed doses in whole body as compared to previous studies. This 
difference is mainly caused by the high residence time in the remainder of body in 
patient 1. The mean organ absorbed doses in the remaining organs were comparable to 
the values observed by previous studies.  
Pre-therapeutic dosimetry aims at improving and tailoring dose delivery to tumor 
lesions while maintaining safety and avoiding toxicity to normal organs. With previous 
knowledge from the literature, we mainly considered the kidneys, bone marrow and 
salivary gland toxicity as organs at risk for the potential development of side effects.  
Using extrapolated organ absorbed doses, the maximum permissible activity 
(GBq) with [177Lu]Lu-PSMA-617 to reach EBRT based organ absorbed dose limits (table 
18) was calculated. This revealed varying results among patients. In patient 1 bone 
marrow toxicity limits were reached earlier than the kidney toxicity limits, however the 
whole body toxicity limit was reached at even lower activity, which might require strict 
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monitoring and possibly dose reduction in this patient when performing [177Lu]Lu-PSMA-
617 therapy. This finding is consistent with the compromised renal function and high 
skeletal tumor burden in this patient, which together result in a high dose to the total 
body.  
In patient 2 bone marrow toxicity limits constrained the maximum permissible 
activity and the maximum number of cycles that can be administered, which is 
consistent with the observation already discussed in the literature  that high skeletal 
tumor burden and can result in high bone marrow absorbed doses, which might lead to  
grade 1-2 hematological toxicity  from [177Lu]Lu-PSMA-617, especially when bone 
marrow function is already compromised owing to prior extensive treatment with 
chemotherapy/radiotherapy (Emmett et al., 2017). In the remaining three patients kidney 
toxicity thresholds appeared to be the dose limiting factor. The number of 6 GBq cycles 
keeping in view the above-mentioned dose limiting toxicities, it was found that except for 
patient 1, administration of up to 5 cycles of 6 GBq seems to be feasible. 
Though the kidneys were an organ at risk with high organ absorbed doses, we 
found that in order to reach EBRT-derived dose limit of 23 Gy, a mean cumulative 
activity of 52 GBq can be administered. It is apparently higher than values found in 
literature for [177Lu]Lu-PSMA-617, which were  calculated  to be 30 GBq by Kabasakal et 
al (Kabasakal et al., 2015). a difference that can be explained owing to 2D versus 3D 
dosimetry inherent limitations.  Moreover, A. Delker et al used 3D SPECT of abdomen 
for dosimetric analysis of [177Lu]Lu-PSMA-617 and reported a mean absorbed dose of 
0.6 GY/GBq for kidneys which may allow up to 38 GBq to be administered safely (Delker 
et al., 2016). Use of mono-exponential non-linear least squares fit to time activity curve 
and a linear interpolation from time of injection in contrast to bi-exponential curve fitting 
and availability of dynamic data from time of injection in our current study might be the 
cause of this disparity between A Delker et al and our current study. Moreover, it is also 
believed that toxicity limit for kidneys with [177 Lu]Lu-PSMA-617 therapy should be 
increased (Emmett et al., 2017).  
Considering 25 Gy as dose limit for reversible toxicity to salivary glands it was 
seen that  even in patient 2 with highest salivary glands absorbed dose  it was not a 
limiting factor for permissible activity calculation in  that patient (Emmett et al., 2017).The 
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finding is supported with evidence of 4-25% occurrence of transient reversible 
xerostomia and dry mouth with [177Lu]Lu-PSMA-617 therapy in various studies.  
Our current study shows that the conversion from pre-therapeutic 
pharmacokinetic data obtained by [44Sc]Sc-PSMA-617 PET/CT to potential normal organ 
absorbed doses for [177Lu]Lu-PSMA-617 therapy is feasible. It might prove to be helpful 
in the pre-therapeutic assessment of organs at risk, which seem to be are variable 
among patients, and eventually aid in tailoring personalized PSMA-targeted radionuclide 
therapy regimens. However, further large scale studies are warranted to validate 
extrapolated organ doses from pre-therapeutic [44Sc]Sc-PSMA-617 PET/CT with post-
therapeutic [177Lu]Lu-PSMA-617 dosimetry data and to correlate dosimetry results with 
clinical toxicity and side effects.  
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5 Abstract 
Introduction: The availability of imaging and therapeutic radionuclides directed against 
same molecular targets has actualized theranostics and possibility of personalized 
treatment in nuclear medicine. For personalized medicine with maximum effect of 
therapy at target with therapeutic radionuclide, diagnostic radionuclide is required to 
select appropriate patient that can benefit from therapy and tailor the therapeutic doses 
with possible prospective dosimetric analysis for therapeutic radionuclides. Hence 
necessitates biodistribution and dosimetric analysis of diagnostic as well as therapeutic 
radionuclide. In this study, the biodistribution and dosimetric analysis of [68Ga]Ga-
DOTAZOL and [177Lu]Lu-DOTAZOL (specific bone seeking radiopharmaceuticals) in 
patients with skeletal metastatic disease and [44Sc]Sc-PSMA-617 (nonspecific bone 
seeking radiopharmaceutical) in mCRPC patients  has been assessed to establish their 
feasible theranostic use. Further, possibility of calculation of normal organ absorbed 
doses for [177Lu]Lu-DOTAZOL and [177Lu]Lu-PSMA-617 with  [68Ga]Ga-DOTAZOL and 
[44Sc]Sc-PSMA-617 respectively has been explored. Materials and Methods: A total of 
fourteen patients were enrolled for biodistribution and dosimetric analysis; five for 
[68Ga]Ga-DOTAZOL (mean age: 72 y), four for [177Lu]Lu-DOTAZOL (mean age: 69.3 y)and 
05 patients for [44Sc]Sc-PSMA-617 (mean age: 69 y). PET/CT scintigraphy (dynamic + 
static skull to mid-thigh) along with blood and urine samples for [68Ga]Ga-DOTAZOL and 
[44Sc]Sc-PSMA-617 and gamma camera planar whole body scintigraphy with blood 
samples collection  for [177Lu]Lu-DOTAZOL at multiple time points was used to determine 
the kinetics of respective radiopharmaceuticals. For quantitative analysis of PET/CT 
studies for [68Ga]Ga-DOTAZOL and [44Sc]Sc-PSMA-617  interview fusion software 
(MEDISO Medical Imaging Systems, Budapest, Hungary) was used. Percent of injected 
activities in source organs, blood and urine samples was used to perform kinetic 
analysis, residence time (MBq-h/MBq) and organ absorbed dose determination using 
OLINDA/EXM version 2.0 software (Hermes Medical Solutions, Stockholm, Sweden). To 
determine residence times and organ absorbed doses with OLINDA/EXM version 2.0 
software (Hermes Medical Solutions, Stockholm, Sweden) for [177Lu]Lu-DOTAZOL, 
percent of injected activity in source organs was determined using EANM dosimetry 
guidelines and methodology explained in MIRD pamphlet no 16. For prospective 
  69  
 
dosimetric analysis the pharmacokinetic analysis of [68Ga]Ga-DOTAZOL and [44Sc]Sc-
PSMA-617  was mathematically extrapolated  for [177Lu]Lu-DOTAZOL and [177Lu]Lu-
PSMA-617 respectively. Results: Biodistribution and dosimetric analysis of [68Ga]Ga-
DOTAZOL revealed urinary bladder  as critical organ with highest absorbed dose (0.338 
mSv/ MBq) and skeleton as target organ. Besides high urinary bladder and kidney 
absorbed doses, mean effective dose was found similar to [18F]NaF. Its biodistribution 
was also found comparable with [18F]NaF, [99mTc]Tc-MDP and [68Ga]Ga-PSMA-617. 
Biodistribution and dosimetric analysis of [177Lu]Lu-DOTAZOL showed early, high uptake 
in kidneys with fast clearance and gradual rise of activity in skeleton. Mean organ 
absorbed doses were highest in osteogenic cells (3.33 MSv/ MBq) followed by kidneys 
and red marrow. Maximum permissible activity was limited due to bone marrow toxicity. 
Prospective dosimetry with [68Ga]Ga-DOTAZOL resulted in lower organ absorbed doses  
and lower therapeutic doses for [177Lu]Lu-DOTAZOL. Biodistribution of [44Sc]Sc-PSMA-
617 was found similar to [68Ga]Ga-PSMA but with higher organ absorbed doses and 
lower effective dose. Kidneys with highest radiation absorbed dose of 0.319 mSv/ MBq 
were the critical organs, followed by urinary bladder wall and rest of organs. Prospective 
dosimetric analysis of [177Lu]Lu-PSMA-617 from extrapolated pharmacokinetics of 
[44Sc]Sc-PSMA-617 revealed highest absorbed dose in the kidneys (0.44 mSv/MBq) 
followed by the salivary glands (0.23 mSv/MBq). The maximum permissible activity was 
highly variable among patients; limited by whole body absorbed dose (one patient), 
marrow absorbed dose (one patient) and kidney absorbed dose (three patients). 
Conclusions: [68Ga]Ga-DOTAZOL and [177Lu]Lu-DOTAZOL can be employed for 
theranostics in patients with skeletal metastatic disease. [68Ga]Ga-DOTAZOL needs to be 
used with diuretics to reduce absorbed doses to urinary bladder and kidneys. Moreover 
[68Ga]Ga-DOTAZOL is not appropriate for prospective dosimetric analysis of [177Lu]Lu-
DOTAZOL. The longer lived [44Sc]Sc-PSMA-617 has been found an important theranostic 
radionuclide for diagnosis, follow up and probable pre-therapeutic personalized 
dosimetric analysis  for [177Lu]Lu-PSMA-617 in mCRPC  patients.  
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